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ABSTRACT 
A novel role of human DNA damage checkpoint protein ATR in suppressing Ca2+ 
overload-induced PARP1-mediated necrosis 
by 
 Hui Wang-Heaton 
Ataxia telangiectasia and Rad3-related (ATR) is well known for its regulatory role in 
DNA damage responses (DDR) as a checkpoint kinase that phosphorylates hundreds of 
protein substrates. However, its role in cellular non-DNA damage stress responses 
(NDDR) is unknown. Necrosis is one form of cell death and traditionally has been 
regarded as a passive and uncontrolled cell death. Recently, evidence has emerged to 
support the concept that necrosis also may occur in a programmed manner and that poly 
(ADP-ribose) polymerase 1 (PARP1) can be a mediator. Active PARP1 hydrolyzes 
nicotinamide adenine dinucleotide (NAD+) to produce poly (ADP-ribose) (PAR) 
polymers on target proteins or itself. As a result, hyper-activity of PARP1 may lead to 
necrosis by excessively depleting ATP pool which results in mitochondrial energetic 
collapse. On the other hand, it is known that Ca2+ overload induces necrosis, but much 
still remains unknown about how Ca2+ overload-induced necrosis is regulated in cells. In 
this study, we show that ATR, besides its hallmark regulatory role in DDR, also plays a 
role in NDDR by suppressing ionomycin-induced necrosis. Ionomycin as a Ca2+ 
ionophore can dramatically raise the intracellular level of Ca2+, leading to necrosis. We 
found that this Ca2+ overload-induced necrosis occurs without inducing DDR in cells. 
Instead, the hyper-poly(ADP-ribosyl)ation (PARylation) activity of activated PARP1 
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could be a reason leading to necrosis, as NAD+ supplied to media can rescue ionomycin-
induced necrosis. In vitro PARylation assay also demonstrates that PARP1 hyper-
activation is Ca2+ dependent. In cells, ATR-PARP1 interaction happened after ionomycin 
treatment. Furthermore, ionomycin treatment induces more full-length PAR polymers 
formed in ATR-deficient cells than in ATR-proficient cells. The interaction of kinase-
dead ATR and PARP1 dramatically decreased as compared to wild-type ATR. Therefore, 
ATR plays a novel role in NDDR wherein it is able to suppress Ca2+ overload-induced 
PARP1-mediated necrosis. Ca2+ overload-induced cell death is a major cause of many 
human medical conditions and diseases, such as brain injury, stroke and ischemia etc. 
Our ongoing studies will help to define the molecular mechanisms of the anti-necrosis 
activities of ATR, which may support ATR as a new clinical target for therapeutic 
treatment of those diseases. 
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CHAPTER 1 
INTRODUCTION 
 
DNA Damage Checkpoint Kinase ATR 
 
ATR, ataxia telangiectasia and Rad3-related, is well known for its regulatory role 
in the DNA damage responses (DDR). Its critical function has been shown in maintaining 
genome integrity against DNA damage induced by endogenous or environmental sources 
(Nyberg et al. 2002; Zou and Elledge 2003; Cimprich and Cortez 2008). Upon induction 
of genomic stress, ATR and ataxia telangiectasia mutated (ATM) activate the 
checkpoint-signaling pathway to induce cell cycle arrest, DNA repair, and/or apoptosis to 
eliminate the damaged cells (Sancar et al. 2004; Wu et al. 2006) (Figure 1).  
Figure 1: Schematic of DNA damage checkpoint activation following IR/UV 
radiation (Used with permission by Dr. Yue Zou). 
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ATR and ATM are two members of the phosphoinositide 3-kinase-related protein 
kinase (PIKK) family of protein kinases and are the sensors of genomic stress (Abraham 
2001) (Figure 1). ATR is activated by DNA damage-induced replicative stress, while 
ATM is primarily activated by DNA double-strand breaks (DSBs) (Smith et al. 2010; 
Zeman and Cimprich 2014). ATR detects genomic stress and then regulates the cellular 
signaling pathways by phosphorylating downstream protein substrates. Chk1 and p53 are 
two major substrates of ATR (Tibbetts et al. 1999; Liu et al. 2000; Toledo et al. 2011) 
(Figure 1). ATR, as a checkpoint kinase, preferentially phosphorylates its substrates on 
serine or threonine residues that are followed by a glutamine residue (SQ/TQ motif) (Kim 
et al. 1999; Traven and Heierhorst 2005; O’Neill et al. 2000). For example, ATR 
phosphorylates p53 at serine 15 and Chk1 at serine 345, which are all followed by a 
glutamine residue (Tibbetts et al. 1999; Liu et al. 2000; Toledo et al. 2011). 
 
Mechanisms of ATR Activation in DDR 
As mentioned above, ATR primarily responses to DNA damage-induced 
replicative stress and single-stranded DNA (ssDNA) (Burrows and Elledge 2008) (Figure 
2). Replication protein A (RPA), is a ssDNA-binding protein, which binds at sites of 
DNA damage-induced ssDNA. ATR interacting protein (ATRIP), the regulatory partner 
of ATR, interacts with RPA and then ATR-ATRIP protein complex is recruited to sites of 
DNA damage (Laplante and Sabatini 2009; Smith et al. 2010; Liu et al. 2012) (Figure 2). 
In other words, RPA-mediated recruitment of ATR-ATRIP protein complex to ssDNA is 
needed for ATR kinase activation in human cells (Zou and Elledge 2003; Namiki and 
Zou 2006; Cortez 2001). DNA topoisomerase II binding protein 1 (TopBP1) later is 
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recruited to the ssDNA site to interact with ATR-ATRIP protein complex. The ATR-
activating domain (AAD) of TopBP1 stimulates the kinase activity of ATR for the 
phosphorylation of ATR’s substrates like Chk1 (Higgs and Peterson 2005; Kumagai et al. 
2006; Ball et al. 2007, Xu and Leffak 2010) . It was reported that the AAD of TopBP1 is 
important for the stimulation of ATR-ATRIP activity for DNA-damage-checkpoint 
activation (Kumagai et al. 2006). Interestingly, TopBP1 is phosphorylated by ATR and 
the phosphorylation on TopBP1 enhances the interaction between TopBP1 and ATR-
ATRIP. TopBP1 activates the ATR-ATRIP complex, which is followed by ATR 
phosphorylation of TopBP1. This phenomenon promotes a positive feedback loop to 
amplify ATR-mediated DNA damage checkpoint signaling (Yoo et al. 2007).  
Figure 2: ATR activation in conserved ATR-Chk1 checkpoint signaling 
pathway (modified from Xu and Leffak 2010). ATR-ATRIP is recruited to 
RPA-coated ssDNA by interaction of ATRIP and RPA. Then TopBP1 is 
recruited to RPA-coated ssDNA by interacting with ATR-ATRIP, followed 
by activation of ATR. Activated ATR phosphorylates Chk1. 
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Phosphorylation of threonine (Thr)-1989 on ATR is a marker of ATR activation, 
and this phosphorylation is DNA damage regulated. However, non-phosphorylatable 
ATR protein mutant (T1989A) still can enable cells with DNA damage-induced ATR 
checkpoint signaling pathway (Nam et al. 2011). It was reported that ATR activation 
relies on RPA, ATRIP, and ATR kinase activity (Liu et al. 2012).  
 
ATR Is Essential for Cell Viability 
In contrast to ATM, ATR is essential for the viability of human and mouse cells. 
Mouse model studies have shown that ATR knockout causes early embryonic lethality 
(Brown and Baltimore 2000; De Klein et al. 2000; O’Driscoll 2009). An array of studies 
has shown that ATR inhibition decreases carcinogenesis. Caffeine, an inhibitor of ATR, 
has been shown to be an inhibitor of several cellular processes, including activation of 
ATM and ATR (Sarkaria et al. 1999). It was reported that there is a link between 
caffeinated beverage intake and significant decreases in several types of cancer, including 
highly prevalent UV-associated skin carcinomas (Heffernan et al. 2009; Kawasumi et al. 
2011). It is known that UV irradiation-induced mild DNA damage initiates cell cycle 
progression arrest and promotes DNA damage repair. If DNA damage is overwhelming, 
apoptosis will be induced to eliminate the damaged cells. Additionally, ATR-Chk1 
pathway inhibition promotes apoptosis after UV treatment in primary human keratinocyte 
(Heffernan et al. 2009). Taken together, these findings indicate that ATR inhibition is an 
effective target in cancer prevention (Weber and Ryan 2015).  
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Cell Death Is a Critical Defense Mechanism 
 
Cell death is a critical defense mechanism for maintaining homeostasis of an 
organism and for its survival. In general, when cells experience stress high enough to 
jeopardize homeostasis, cell death is initiated to selectively eliminate damaged cells for 
the wellbeing of the organism. The fact that more than 50% of human cancers are p53 
deficient demonstrates that cell death plays a pivotal role in suppressing tumorigenesis. 
When cells undergo overwhelming stress, such as irreparable DNA damage, the p53 
tumor suppressor activates one type of cell death, named apoptosis, through DNA 
damage checkpoint pathways (Mihara et al. 2003; Zilfou et al. 2012). On the other hand, 
abnormal cell death is the cause of many human diseases including cardiovascular, 
infection/allergy, and immune system diseases (Favaloro et al. 2012; Matt and Hofmann 
2016). Thus, a proper balance between cell death and survival is important for the 
wellbeing of a multicellular organism. 
What is the standard to determine the death of a cell? The Nomenclature 
Committee on Cell Death (NCCD) suggests that a cell should be considered dead when it 
has gone through any one of the following molecular or morphological situations: ① the 
loss of the integrity of the cellular plasma membrane; ② the complete fragmentation of 
the cellular nucleus into discrete bodies; ③ the engulfment of the cellular corpse (or 
cellular fragments) by an adjacent cell in vivo (Kroemer et al. 2009; Alvarez et al. 2010). 
The catalogs of cell death have relied on morphological features before 
considering biochemical or molecular biological tests that are available for assessing cell 
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demise. In 1973, Schweichel and Merker proposed three types of cell death modalities.  
The first type is “Type I cell death” associated with heterophagy, the second type is 
“Type II cell death” associated with autophagy, and the last type is “type III cell death”, 
which was not associated with any type of digestion. These three types of cell death 
correspond to apoptosis, autophagy, and necrosis, respectively (Anon n.d.; Galluzzi et al. 
2007; Kroemer et al. 2009). The morphological appearance of these three types of cell 
death is shown in Figure 3. 
Figure 3: Three types of cell death (modified from Escobar-Sánchez et al. 2015). (a) 
Necrosis is characterized as cell swelling, plasma membrane rupture. (b) Apoptosis. Cell 
shrinkage and formation of apoptotic bodies characterizes apoptosis. (c) Autophagic cell 
death. Formation of autophagosome, which are characterized as typical double membrane, 
indicating autolysis has occurred. Cell organelle disruption. 
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Necrotic Cell Death 
 
Necrosis Is a Controlled Cell Death  
Necrotic cell death was traditionally thought to be an accidental and uncontrolled 
cell death pathway resulting from cellular infection or physicochemical stress, such as 
mechanical force, heat or cold. The morphology of necrotic cell death is characterized by 
cytoplasmic swelling, irreversible and rapid loss of plasma membrane integrity, and 
spillage of the intracellular components (Proskuryakov et al. 2003; Festjens et al. 2006; 
Krysko et al. 2008) (Figure 4).  
Figure 4: Morphology of necrosis and apoptosis (modified from Carella 2003). (a) 
Necrosis is characterized as cell swelling, plasma membrane rupture. (b) Apoptosis. Cell 
shrinkage and formation of apoptotic bodies characterizes apoptosis. 
 
A growing body of evidence has indicated that necrotic cell death also plays an 
important role in the maintenance of the physiologic condition of the cell. For example, 
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necrosis may serve to maintain tissue and organism integrity by initiating inflammatory 
responses in the host. High mobility group box 1 (HMGB1) protein is a nuclear protein 
that is released from necrotic cells and acts as a signaling molecule to inform neighboring 
cells that tissue repair is required (Harris and Andersson 2004; Zong and Thompson 2006; 
Han et al. 2008; Cho et al. 2010). Further research has shown that necrotic cell death 
occurs during many human pathological diseases (shown in Table1). All these suggest 
that necrosis is a type of programmed cell death. 
Table1: Pathologies associated with necrotic cell death (modified 
from Proskuryakov et al. 2003; Conrad et al. 2016) 
Pathology Cells 
Alzheimer disease Neurons 
Inflammatory diseases Islet cells 
Infection Lymphocytes 
 Hepatocytes 
 Neutrophils 
 Macrophages 
Ischemia Various cells (myocardial cells, endothelial 
cells, neurons et al.) 
 
Since much of the knowledge about necrosis is still lacking, more studies on the 
molecular mechanisms of necrotic cell death are necessary. A mechanistic understanding 
of necrosis is important for drug development for human diseases related to necrosis. 
Recently, necrosis has become a major interest in disease research and cancer therapy.   
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ATP Depletion Is a Hallmark Event of Necrosis, which Is Poly(ADP-Ribose) 
Polymerase1 (PARP1) Related 
Unlike apoptosis, which is energy dependent, necrosis is characterized by 
bioenergetic catastrophe. The collapse or failure of energy (adenosine triphosphate, ATP) 
production in cells is a hallmark event of necrosis. Thus, any mechanisms by which ATP 
is depleted could be linked to necrosis. Cellular stress resulting from nutrient starvation 
or a reduced oxygen supply often results in ATP depletion.  In solid tumors, necrosis is 
commonly found in the internal region where insufficient vascularization causes oxygen 
and glucose depletion (Zong and Thompson 2006).   
Poly(ADP-ribose) polymerase (PARP) protein family comprises 17 members and 
the primary function of this family of proteins is to generate adenosine diphosphate 
ribose (ADPR) modifications on target proteins using nicotinamide adenine dinucleotide 
(NAD+) as a substrate (Figure 5).  
Figure 5: Structure of NAD+ (modified from Curtin 2005). PARP cleaves NAD+ 
and liberates ADPr and nicotinamide (NAM) (red), and ADPr can be polymerized via 
linear or branched attachment points to the 2’-hydroxyl of the ribose. 
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There are two types of ADPr modification, one is poly(ADPr) (PAR) 
modification and the other is mono(ADPr) (MAR) modification. MAR modification is 
when only one ADPr is covalently bound to the modification site(s) of a target protein. 
PAR polymers are synthesized by covalently binding of ADPrs through linear or 
branched attachment points (Kawaichi et al. 1981; Amé et al. 2004; Li and Chen 2014; 
Curin 2005) (Figure 5). The ADPr modification function of each PARP family protein is 
summarized in Table 2. 
Table2: Summary of PARP enzymatic activities (modified from Vyas 2014) 
Activity PAR MAR Inactive 
PARP 1 2 5a 5b 3 4 6 7 8 10 11 12 14 15 16 9 13 
 
When PARP1 is activated, it can hydrolyze NAD+ into nicotinamide (NAM) and 
ADPR (Figure 5). PARP1 covalently binds ADPR to a carboxyl group on itself or its 
substrates through hydrogen bound. ADPRs are covalently bound together to form PAR 
polymers (Figure 6). Decades ago, auto-PARylation of rat liver PARP1 showed that the 
enzyme-bound polymers formed branch structures at a frequency of one in every 50 
ADPR units. There were as many as 15 ADPR polymers on each enzyme (Modification 
et al. 1981). PARP1’s ability to add PAR polymers onto itself or its substrates is termed 
PARylation activity (Figure 6). 
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Figure 6: PARylation activity of PARP1 (modified from Fischer et al. 2014). The NAD+ 
is hydrolyzed into NAM and ADPR, and ADPRs are covalently connected to a carboxyl 
group of itself or its substrates to form PAR polymers. 
 
PARP1 hyper-activation was demonstrated to be a cause of necrotic cell death by 
leading to ATP depletion (Ha and Snyder 1999; Zong et al. 2004; Park et al. 2015) 
(Figure 5).  PARP1 is responsible for producing up to 90 % of PAR levels within cells 
(D’Amours et al. 1999; Bürkle 2005; Yelamos et al. 2011). PARP1 plays a crucial role in 
many cellular physiological and pathological processes, including DNA repair and cell 
death. PARP1 is located in the nucleus, can be activated by genomic stress, and 
physiologically participates in DNA repair (Dantzer et al. 2006; Poirier 2012). Hyper-
activation of PARP1 has been shown to cause the excessive consumption of NAD+ in 
cells, which results in glycolytic activity blockage. This leads to the fall in ATP and the 
accumulation of phosphorylated sugars (Ying et al. 2003). Furthermore, the depletion of 
NAD+/ATP pool leads to necrosis due to the metabolic collapse (Figure 7). Also, 
oxidative stress-induced hyper-activation of PARP1 causes excessive NAD+ consumption 
and consequently ATP depletion, leading into cell necrosis (Sriram et al. 2016). 
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Figure 7: Hyper-activation of PARP1 leads to necrosis via ATP depletion (modified from 
Ström and Helleday 2012). Hyper-activation of PARP1 causes excessive consumption of 
NAD+/ATP pool. At extremely low levels of ATP, the cell rapidly dies through necrosis 
as a result of acute energy depletion. 
 
Necrosis Is Independent of Cleavage of Caspase 3, Caspase 7 And PARP1 
When cells go through apoptotic cell death, an early transient burst of PAR 
modification of nuclear proteins by PARP1 is required. However, before the depletion of 
the NAD+/ATP pool, PARP1 is inactivated by cleavage catalyzed by caspase 3, 
generating a 24 kDa DNA-binding domain (DBD) and another 89 kDa catalytic fragment 
(Kaufmann et al. 1993; Boulares et al. 1999; D’Amours et al. 2001). The cleavage of 
PARP1 in cells going through apoptosis is not alone, the cleavage of caspase 3 and 
caspase 7 is required for the activation of caspase 3 and caspase 7. In contrast to 
apoptosis, necrotic cell death is independent of cleavage of caspase 3, caspase 7 and 
PARP1 (Lazebnik et al. 1994; Ha and Snyder 1999; Kitanaka and Kuchino 1999; Bröker 
et al. 2005). 
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Necrosis as a Programmed Cell Death via Hyper-Activation of PARP1-Induced ATP 
Depletion 
Although necrotic cell death has been traditionally considered as a passive and 
uncontrolled progress, more evidence has emerged to support the concept that necrosis 
also may occur in an actively programmed manner (Proskuryakov et al. 2003; Festjens et 
al. 2006; Zong and Thompson 2006; Alvarez et al. 2010; Kung et al. 2011; Chavez-
Valdez et al. 2012; Ouyang et al. 2012; Vanden Berghe et al. 2014; Conrad et al. 2016). 
For example, parthanatos, one form of necrosis, is believed to be a form of regulated 
necrosis. It is characterized by hyper-activation of nuclear protein PARP1 by an array of 
stimuli, such as DNA damage and reactive oxygen species (ROS) (Conrad et al. 2016; 
Virág et al. 2013)  (Figure 8). DNA damage initiates parthanatos via production of PAR-
modified apoptosis inducing factor (AIF) (Figure 8, number 1 process). Translocation of 
AIF from mitochondria to the nucleus induces chromatin degradation (Figure 8, number 
2 process). Large scale DNA fragmentation causes necrotic cell death. Last but not least, 
PARP1 is hyper-activated during the regulated necrotic cell death (Figure 8). 
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Figure 8. DNA damage-induced parthanatos (modified from Conrad et al. 2016). DNA 
damage inducer/reagent initiates the hyper-activation of PARP1 in nucleus and the PAR 
modification of AIF at mitochondria. AIF translocated from mitochondria to the nucleus 
induces the degradation of chromatin to produce large scale DNA fragmentation 
following by necrotic cell death. 
 
Ca2+ May Be a Mediator of Necrosis via Hyper-Activation of PARP1 
Bentle et al. reported in 2006 that when cells undergo stress of ROS and DNA 
breaks, necrotic cell death was induced through Ca2+-dependent PARP1 hyper-activation 
(Bentle et al. 2006). Later, several reports demonstrated that Ca2+ is a mediator of 
necrotic cell death and may be responsible for the hyper-activation of PARP1-mediated 
necrosis via NAD+/ATP pool depletion in cells (Yang et al. 2007; Francis et al. 2013; 
Douglas and Baines 2014; Zhang et al. 2014). Nonetheless, the molecular mechanism 
leading to necrosis remains elusive.  
Under physiological conditions, cells maintain a cytosolic free- Ca2+ 
concentration of roughly 100 nM in contrast to ~1.2 mM extracellular concentration; a 
spike of cytosolic Ca2+ to 200-400 nM due to release from the endoplasmic reticulum 
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(ER), for example, can induce apoptosis; in contrast, a cytosolic concentration of Ca2+ 
higher than 1 μM resulting from influx across the plasma membrane triggers necrosis 
(McConkey and Orrenius 1996; Zong and Thompson 2006). For example, Ca2+ overload 
is a critical step of hydrogen peroxide (H2O2)-induced necrotic cell death. The 
morphology of dying cells are featured with their plasma membrane swelling and loss of 
the integrity of the plasma membrane. H2O2 treatment induces massive Ca2+ influx and 
intracellular Ca2+ levels were measured to be a maximum concentration of 1200 nM. 
Interestingly, the Ca2+ channel inhibitor cobalt was able to blunt this Ca2+ influx, blocked 
necrosis and rescued the cells from H2O2–induced death (Li et al. 2010). Additional 
research demonstrated that deregulation of mitochondrial activity is the consequence of 
Ca2+ influx in cells. The decreased mitochondrial activity lead to increased ROS levels 
and dramatically reduced levels of ATP. This resulted in the induction of necrotic cell 
death in the cells (Zong and Thompson 2006; Kennedy et al. 2009). 
How necrosis is regulated in cells remains largely unknown, particularly the 
mechanism of Ca2+ overload-induced necrosis. Necrosis induced by Ca2+ overload 
contributes to diseases such as heart failure, ischemic stroke, brain injury and immune 
diseases (Kristián and Siesjö 1998; Nakayama et al. 2007; Monassier 2008; Kalogeris et 
al. 2012). It is of utmost importance to investigate the biochemical and molecular-
mechanisms behind Ca2+ overload-induced necrotic cell death. 
 
Human PARP1 protein 
Human PARP1 protein includes three domains: ① a N-terminal zinc finger DBD, 
including three zinc finger domains FI, FII and FIII (Figure 9), which contribute to 
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binding to a variety of DNA structures such as single- and double-strand breaks, 
crossovers, some specific double-stranded sequences (Kim et al. 2005), as well as a 
nuclear localization signal (NLS) domain, ② a central auto-modification domain 
containing a BRCA1 C terminus (BRCT) fold and linker regions that contain major sites 
targeted for PARP1 auto-modification. The WGR domain participates in DNA binding, 
and ③ a C-terminal catalytic domain containing two subdomains: a helical domain (HD) 
that is conserved in DNA damage-dependent PARPs 1, 2, and 3, and the ADP-
ribosyltransferase (ART) domain that contains the active site and a fold that is conserved 
in all PARP family members ( Kim et al. 2005; Tao et al. 2009; Eustermann et al. 2011; 
Dawicki-McKenna et al. 2015). 
Figure 9: Schematic diagram of human PARP1 domains (modified from Yelamos et al. 
2011; Dawicki-McKenna et al. 2015). The depiction of human PARP1 shows the relative 
sizes and locations of DNA binding domain, auto-modification domain and catalytic 
domain. 
 
Glutamic Acid 988 Is Essential for the PARylation Activity of PARP1 
Marsischky et al. demonstrated that glutamic acid (E) 988 of PARP1 is essential 
for the synthesis (especially the elongation) of enzyme-linked PAR polymers. E988 is 
located in the C-terminal catalytic domain of PARP1 (Marsischky et al. 1995). Mutated 
PARP1 protein was produced by mutagenesis of E988 to glutamine (Q) or Alanine (A). It 
was shown that mutated PARP1 is devoid of elongation activity (2800-fold reduction) 
(Rolli et al. 1997).   
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Aim of the Study 
Cell death plays a critical defense role in maintaining homeostasis of an organism 
and for its survival. A proper balance between cell death and survival is important for the 
wellbeing of a multicellular organism. There are three major types of cell death, 
apoptosis, autophagic cell death and necrosis. Unlike apoptosis and autophagic cell death 
which are programmed cell death, necrosis has traditionally been considered as passive 
and uncontrolled cell death. But recently, more and more evidence has been reported to 
support the concept that necrosis is a regulated process.  
PARP1 was demonstrated as a mediator of necrosis via hydrolyzing NAD+ to 
produce PAR polymers on target proteins or itself. Hyper-activation of PARP1 leads to 
necrotic death due to cellular metabolic collapse resulting from excessive consumption of 
NAD pool (Ha and Snyder 1999; Zong et al. 2004; Park et al. 2015). And it was reported 
that Ca2+ overload resulting from influx across the plasma membrane triggers necrosis 
(McConkey and Orrenius 1996; Zong and Thompson 2006). However, much still remains 
unknown about how necrosis is regulated in cells.  
ATR, a PI3K family member, is best known for its regulatory role in DDR. Upon 
genomic stress, it senses the cellular stress and works as a checkpoint kinase to 
phosphorylate hundreds of its substrates, such as p53 and Chk1 (Figure 1). ATR/p53 
checkpoint signaling pathways play a decisive role in determining cell fate (growth arrest 
or apoptosis) (Wu et al. 2006; Vousden and Lane 2007; Wu et al. 2007; Shell et al. 2009; 
Zhang et al. 2009; Li et al. 2011; Zilfou et al. 2012; Kracikova et al. 2013; Li et al. 2013; 
Serrano et al. 2013; Hilton et al. 2015).  Given the important role of ATR in regulating 
cellular responses to genomic stress, we asked the question of whether ATR also could be 
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a regulator of necrosis. Indeed, our data showed that cells treated with ionomycin had a 
much higher rate of necrotic cell death in the absence of ATR than in the presence of 
ATR. Five hypotheses were proposed as follows: 
1. ATR plays a role in NDDR wherein it is able to suppress ionomycin-
induced necrosis due to Ca2+ overload. 
2. Ionomycin treatment hyper-activates the poly(ADP-ribosyl)ation 
(PARylation) activity of PARP1. 
3. Ionomycin treatment induces physical interaction of ATR and PARP1 for 
suppressing necrosis. 
4. The anti-necrosis function of ATR depends on its kinase activity. 
5. Ca2+ itself hyper-activates the PARylation activity of PARP1 and primes 
PARP1 for ATR binding. 
Research shows that necrotic cell death happens during many human pathological 
diseases (Table 1). Our ongoing studies will help to define the molecular mechanisms of 
the anti-necrotic cell death activities of ATR relevant to human diseases. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
Materials 
 
The materials that are listed below have been used for the research during Ph.D. study: 
Table 3: General laboratory reagents, chemicals 
Name Manufacturer 
1kb DNA ladder, GeneRuler ThermoFisher Scientific 
2-Mercaptoethanol (2-ME) Sigma-Aldrich 
30% acrylamide/bis Solution 29:1 Bio-Rad 
6 X DNA loading dye ThermoFisher Scientific 
Acrylamide Bio-Rad 
Agar (Miller’s LB) IBI Scientific 
Agarose ThermoFisher Scientific 
Ampicillin Research Products International Corp. 
Bromophenol blue Sigma-Aldrich 
Bovine serum albumin (BSA) Millipore 
Butanol EMD Millipore 
Calcium chloride (CaCl2) Sigma-Aldrich 
Dimethyl sulfoxide (DMSO) ThermoFisher Scientific 
Dithiothreitol (DTT) Research Products International Corp. 
Dulbecco’s modified eagle medium 
(DMEM) with phenol red, 4500 mg/L 
glucose, 4.0 mM L-glutamine, and 110 
mg/L sodium pyruvate 
HyCloneTM Liquid Tissue Culture Media, 
GE Healthcare Life Sciences 
Ethanol (EtOH; molecular grade) Pharmaco-AAPER 
Ethidium bromide (EB) ThermoFisher Scientific 
Fetal bovine serum (FBS) GE Healthcare Life Sciences 
Formaldehyde, 16% Electron Microscopy Sciences 
Gentle ReviewTM Stripping Buffer Amresco® Biochemicals and Life Science 
Research Products 
Glycerol J.T.Baker 
HEPES EM Science 
Hydrochloric acid (HCl) ThermoFisher Scientific 
Hygromycin B ENZO Life Sciences 
Ionomycin (calcium salt) Cayman Chemical 
Isopropanol ThermoFisher Scientific 
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Table 3 (continued) 
Isopropyl-β-D-thiogalactopyranoside 
(IPTG) 
Research Products International 
jetPEITM HTS DNA transfection Reagent Polyplus-transfection 
Methanol (MeOH) BDH 
Microscope slides 25X75X1 mm Fisher Scientific 
Milk powder, non-fat Food Club 
McCoy’s 5A, HyClone Classical Liquid 
Media 
GE Healthcare Life Sciences 
Monopotassium phosphate (KH2PO4) Fisher 
Multiwell dishes: 6-well, 12-well, 24-well 
and 96-well 
Cyto-One 
Neomycin sulfate solution Scientific Sales, Inc 
Nicotinamide adenine dinucleotide (NAD, 
[32P]) 
Perkin Elmer 
Penicillin-streptomycin Hyclone 
Petri dishes: 35mm, 60mm, 70mm, 
100mm and 150mm diameter 
VWR 
Phosphatase inhibitor GBiosciences 
Pierce® 660 nm Protein Assay Reagent ThermoFisher Scientific 
PierceTM Protein G Plus Agarose Beads ThermoFisher Scientific 
Potassium chloride (KCl) ThermoFisher Scientific 
Precision Plus ProteinTM Unstained 
Standards 
Bio-Rad 
Propidium iodide (PI) Sigma-Aldrich 
Protease inhibitor ThermoFisher Scientific 
Halt Protease and Phosphatase Inhibitor 
Cocktail  
ThermoFisher Scientific 
PureProteome Protein G Magnetic Beads EMD Millipore 
Puromycin • 2HCl Enzo Life Sciences 
Sodium dodecyl sulfate (SDS) Amresco 
Sodium chloride (NaCl) EMD 
Sodium phosphate dibasic (Na2HPO4) ThermoFisher Scientific 
Tetramethylethylenediamine (TEMED) ThermoFisher Scientific 
Tris-Acetate 3-8% gradient 
polyacrylamide gels, NuPAGE 
ThermoFisher Scientific/Life 
Technologies 
TRIS base Sigma-Aldrich 
Triton X-100 Sigma-Aldrich 
Trypan blue solution, 0.4 % (w/v) Corning 
Trypsin-Versene Mixture Lonza 
Tryptone Lonza 
Tween 20 Amresco 
Yeast extracts ThermoFisher Scientific 
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Luria broth (LB) medium: 
10 g/L tryptone 
5 g/L yeast extract 
10 g/L NaCl 
pH 7.5 
LB agar medium for LB plate: 
LB medium with 15 g/L agar 
Antibiotic concentration in either LB medium or LB agar plate:  
100 μg/mL ampicillin, was used for selective growth of ampicillin-resistant 
plasmid-transformed E.coli bacteria 
 
50 X TAE electrophoresis running buffer, 1L: 
242 g Tris base 
57.1 mL glacial acetic acid 
100 mL 0.5 M EDTA 
  
Whole cell lysis buffer: 
150 mM NaCl  
50 mM Tris-HCl pH 8.0  
1 % Triton X-100  
1 mM EDTA  
Protease and Phosphatase Inhibitors were added fresh before use. 
PBS (10X, 1L): 
80 g NaCl  
20 g KCl  
14.4 g Na2HPO4 
 2.4 g KH2PO4  
pH was adjusted to 7.4 via pH meter 
ddH2O was added to 1 L. Autoclaved to sterilize. 
Final (1X) working concentration:  
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140 mM NaCl, 27 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4. 
2 X SDS gel-loading buffer: 
100 mM Tris-HCl, pH 6.8 
200 mM DTT (dithiothreitol) 
4 % SDS (sodium dodecyl sulfate, electrophoresis grade) 
0.2 % bromophenol blue 
20 % glycerol 
Tris-glycine electrophoresis buffer (5X, 1L): 
15.1 g Tris base 
94 g glycine  
5 g SDS 
Added ddH2O to 1 L 
Final (1X) working concentration: 25 mM Tris, 250 mM glycine, 0.1 % SDS. 
Transfer Buffer (1L): 
5.8 g Tris base 
2.9 g glycine 
0.37 g SDS 
100 mL methanol 
Added ddH2O to 1L 
Final working concentration: 48 mM Tris, 39 mM glycine, 0.037 % SDS, 10 % methanol. 
 
Table 4: Enzymes for DNA manipulation 
Name Manufacturer 
Alkaline phosphatase, calf intestinal (CIP) New England BioLabs 
FastDigest NdeI ThermoFisher Scientific 
FastDigest XhoI ThermoFisher Scientific 
LongAmp Taq DNA Polymerase New England BioLabs 
T4 DNA Ligase New England BioLabs 
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Table 5: Antibodies 
Name, Catalog Number, Host Manufacturer 
Anti-actin EMD Millipore 
Anti-ATR, A300-137A, rabbit Bethyl Laboratories 
Anti-ATR, A300-138A, rabbit Bethyl Laboratories 
Anti-ATR (phosphor Ser428), 2853, 
rabbit 
Cell Signaling Technology 
Anti-ATR (phosphor Thr1989), 
GTX128145, rabbit 
GeneTex 
Anti-ATRIP, A300-670A, rabbit Bethyl Laboratories 
Anti-Chk1, 2360, mouse Cell Signaling Technology 
Anti-Chk1 (phosphor Ser245), 2348, 
rabbit 
Cell Signaling Technology 
Anti-Cyclophilin A, rabbit GeneTex 
Anti-Cyclophilin D, AP1035, mouse EMD Millipore 
Anti-FLAG M2, F3165, mouse Sigma-Aldrich 
Anti-GAPDH, rabbit Cell Signaling 
Anti-γH2AX, rabbit Bethyl Laboratories 
Anti-Histone H1, GTX87506, rabbit GeneTex 
Anti-Histone H3, rabbit Santa Cruz Biotechnology 
Anti-HMGB1, GTX101277, rabbit GeneTex 
Anti-Myc-Tag, 2276, mouse Cell Signaling Technology 
Anti-p53 (phosphor Ser15), rabbit Cell Signaling Technology 
Anti-PAR, 4335-MC-100, mouse Trevigen 
Anti-PARP1, 9532, rabbit Cell Signaling Technology 
Anti-PARP1, 9542, rabbit Cell Signaling Technology 
Anti-PARP1, sc-8007, mouse Santa Cruz biotechnology 
Anti-PARP1-T368, rabbit OAAB 
Anti-Pin1, 07-091, rabbit EMD Millipore 
Anti-Pin1, GTX113245, rabbit GeneTex 
Anti-Rabbit, 31460, goat ThermoFisher Scientific 
Anti-Goat, sc-2020, donkey Santa Cruz Biotechnology 
Anti-Mouse, 31160, goat ThermoFisher Scientific 
Anti-Mouse, sc-2005, goat Santa Cruz Biotechnology 
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Table 6: Mammalian cell lines and cultural media 
Cell Line Culture Media 
A549, ATCC DMEM + 10% FBS + 1% P/S 
 A549 shCTRL & shPARP1 (From Dr. 
Csaba Szabo, University of Texas 
Medical Branch) 
DMEM + 10% FBS + 1% P/S + 1.5 μg/ml 
puromycin 
HCT116 ATR+/+   McCoy’s 5A + 10% FBS + 1% P/S 
HCT116 ATRflox/-  McCoy’s 5A + 10% FBS + 1% P/S 
HEK293T, ATCC DMEM + 10% FBS + 1% P/S 
SHSY-5Y (From Dr. Meng-Yang Zhu, 
East Tennessee State University, Quillen 
College of Medicine) 
DMEM + 10% FBS + 1% P/S 
U2OS ATR-WT & ATR-KD (From Dr. 
Paul Nghiem, University of Washington 
Medical Center) 
DMEM + 10% FBS + 1% P/S + 0.2 
mg/ml Neomycin + 0.2 mg/ml 
hygromycin, (Doxycycline [5 μg/ml, 24 
hrs] for inducing recombinant ATR-WT 
protein expression) 
 
Table 7: Commercial kits 
Name Manufacturer 
Biotin Chromogenic Detection Kit ThermoFisher Scientific 
CytoTox 96® Non-Radioactive 
Cytotoxicity Assay 
Promega 
Cytoplasmic and Nuclear Protein 
Extraction Kit, ProteoJETTM 
Fermentas Life Sciences 
EZNA® Plasmid DNA Midi Kit I Omerga 
EZNA® Plasmid DNA Mini Kit I Omerga 
In-Fusion HD Cloning Kit  Clontech Laboratories 
NucleoSpin® Gel and PCR Clean-up TaKaRa Clontech 
QIAquick® Gel Extraction Kit Qiagen 
SuperSignal® West Pico 
chemiluminescent Substrate Kit 
ThermoFisher Scientific 
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Methods 
 
Preparation of Competent E.coli Bacterial Cells 
A sterile loop was used to streak the E.coli, either DH5α or BL21 (DE3), on a LB 
agar plate. The E.coli was from frozen glycerol stock in a sterile cryogenic storage vial at 
-80°C freezer. The LB agar plate was put in 37°C incubator overnight. Next day, a 
colony was picked up from the LB agar plate by using a sterile 10 μL micropipette tip or 
toothpick. Dropped the tip or toothpick into a 14 mL polypropylene Falcon tube 
containing 2 mL LB medium. Incubated bacterial culture overnight at 37°C in a shaking 
incubator with 200 rpm. Next day, the cloudy haze culture medium indicated the growth 
of bacteria and the OD600 of the culture medium is around 1.5. Transferred 200 μL of the 
bacterial culture into a 30 mL LB broth in a sterile conical culture flask. Incubated around 
2.5 hrs at 37°C in a shaking incubator with 200 rpm until the OD600 reach around 0.2. 
Transferred the bacterial culture into a 50 mL sterile centrifuge tube and place it on ice 
for 10 mins followed by centrifugation at 2500 rpm for 10 mins at 4°C. Removed the 
supernatant and gently re-suspended the bacteria pellet with 25 mL 100 mM sterile CaCl2. 
Incubated the centrifuge tube containing the re-suspended bacteria on ice for 20 mins 
followed by centrifugation at 2500 rpm for 10 mins at 4°C. Removed the supernatant and 
gently re-suspended the bacteria pellet with 1 mL 100 mM sterile CaCl2. Incubated the 
centrifuge tube on ice for 30 mins. 200 μL of 80 % sterile glycerol was added into the 
centrifuge tube and gently mixed it with re-suspended bacteria. Aliquoted 100 μL of 
mixed bacteria into each 1.5 mL micro-centrifuge tube and snap-frozen in liquid nitrogen. 
Stored the aliquots in -80°C ultralow temperature freezer.  
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Bacterial Transformation with Plasmid 
E.coli competent cells (either DH5α or BL21 (DE3) bacterial cells) is removed 
from -80°C freezer and thawed on ice just before use. LB agar plates (containing 
appropriate antibiotic) are taken out from 4°C and let them warm up in 37°C incubator. 
Set the temperature of the water bath at 42°C. Mix 1 to 5 μL of DNA plasmid (usually 1 
ng to 100 ng) into 50-100 μL of competent cells in a 15 mL micro-centrifuge. Gently 
mixed to ensure even distribution. Placed the tubes containing the competent cells/DNA 
mix on ice for 30 min. Heat shock each transformation tube in the 42°C water bath for 45 
sec. Placed the tubes back on ice for 1-2 min. Add 400-450 μL 37°C warmed LB medium 
to bring the final volume to 500 μL. Incubated by shaking at 200 rpm for 1 hr at 37°C. 
Plated some or all of the transformation onto each 10 cm LB agar plate containing the 
appropriate antibiotic. Plates were incubated at 37°C for 17-19 hrs.  
cDNA Subcloning by Polymerase Chain Reaction (PCR) and Restriction Enzyme 
Digestion 
ATR complementary DNA (cDNA) fragment corresponding to its protein 
fragment (A359-N484) (ATRf) was needed to insert the pTBY2 vector (Result “ATR 
cDNA fragment (A359-N484, ATRf) subclone” section and is shown in Figure 22). 
The purpose of the primer design for amplification of ATR cDNA fragment 
(A359-N484) (ATRf) is to ① amplify the ATR cDNA fragment corresponding to its 
protein fragment A359-N484 from ATR cDNA template, ② add 6 X His tag at the N-
terminal of ATR cDNA fragment, ③ create two recognition sites for restriction enzymes 
(NdeI and XhoI) on the PCR amplified ATR cDNA fragment with 6 X His tag at its N-
terminal. Two primers are:  
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ATRfA359-NdeI-F: 5’-
TGAGGTCATATGCATCACCATCACCATCACGCTGGGTATGAATCTGCT-3’ and  
ATRfN484-XhoI-R: 5’-GGTGGTCTCGAGATTCTTTAGGCCACTGTATTCAAGG-3’.  
 NdeI restriction enzyme’s recognition site is CATATG (underline), while XhoI 
restriction enzyme’s recognition site is CTCGAG (underline). 6 random oligonucleotides 
were added at the very 5’ end of each primer’s recognition site to make sure of the 
cleavage efficiency of each enzyme is > 90 %.  Oligonucleotides of 6 X His tag 
(CATCACCATCACCATCAC, italicized) is added after the 3’ end of NdeI enzyme’s 
recognition site, so the ATR cDNA fragment (A359-N484) is 6 X His tagged.  
ATR cDNA fragment (A359-N484) PCR reaction mix was prepared as follows (50 μL 
PCR mix per reaction): 
ddH2O                                                                                                      31.5 μL  
5 X LongAmp Taq reaction buffer                                                        10 μL 
10 mM dNTPs                                                                                        1.5 μL 
10 μM Forward Primer (ATRfA359-NdeI-F)                                         2 μL 
10 μM Reverse Primer (ATRfN484-XhoI-R)                                         2 μL 
ATR cDNA template plasmid (pcDNA3.1-FLAG-ATR) 1 ng/μL         1 μL 
LongAmp Taq DNA polymerase (0.1 U/μL)                                          2 μL 
Thermo-cycled with the following condition: 
               94°C     5 min 
                             94°C     30 sec 
30 cycles              50°C     60 sec 
                             65°C     20 sec (50 sec/kb of plasmid length) 
               65°C     10 min 
               Hold at 4°C      
5 μL of 50 μL PCR product was loaded on a 1.5 % agarose gel. The PCR 
product’s size should be around 400 base pair (bp). The other 45 μL PCR product was 
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cleaned up by NucleoSpin® Gel and PCR Clean-up kit. Both the PCR products and vector 
of pTYB2 plasmid were double digested by NdeI and XhoI. The double digestion 
reaction was as follows: 
PCR product double digestion (30 μL of mix per reaction): 
ddH2O:                                                                      15 μL 
10 X restriction enzyme digestion buffer                 3 μL  
PCR of ATR fragment (A359-N484) 100 ng/μL     10 μL 
NdeI (10 U/μL)                                                         1 μL 
XhoI (10 U/μL)                                                         1 μL 
 
pTYB2 vector plasmid-double-digestion (20 μL of mix per reaction): 
ddH2O:                                                                      5 μL 
10 X restriction enzyme digestion buffer                 2μL 
pTYB2 vector plasmid (400 ng/μL)                        10 μL 
NdeI (10 U/μL)                                                        1 μL 
XhoI (10 U/μL)                                                        1 μL 
Alkaline Phosphatase (CIP) (10 U/μL)                    1 μL 
Both reactions were incubated in PCR tubes in the thermos-cycler at 37°C for 1 hr.   
Double-digested PCR product (ATR fragment) and double-digested pTYB2 
vector plasmid were cleaned up by using NucleoSpin® Gel and PCR Clean-up kit to get 
rid of salt.  
Ligation of double-digested pTYB2 and PCR product of ATR cDNA fragment 
(A359-N484) as follows (20 μL mix per reaction): 
ddH2O                                                                      5 μL 
10 X T4 DNA ligase buffer                                     2 μL 
Double-digested pTYB2 vector                               6 μL 
Double-digested ATR fragment (A359-N484)        6 μL 
T4 DNA ligase (400 U/μL)                                     1 μL 
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The molar ratio of double-digested pTYB2 vector to double-digested ATR 
fragment is 9:1. 
The reaction mix in a PCR tube was incubated in thermo-cycler at 16°C overnight 
followed by heat inactivation of T4 DNA ligase at 65°C for 10 min. 
5 μL of T4 DNA ligation reaction mixture was used to transform into competent 
DH5α bacteria. Plated the transformed cells on an ampicillin LB agar plate and incubated 
the plate at 37°C for 17-19 hrs.  
Colony picking up and restriction-enzyme double digestion screen colony. A 
sterile 10 μL pipette tip or toothpick was used to pick up one colony from the plate. 
Dropped the tip or toothpick into a 50 mL Falcon tube containing 7.5 mL LB medium 
with 100 ug/mL ampicillin. Four colonies were picked up randomly from the plate and 
each colony was put in one 50 mL Falcon tube followed by incubating at 37°C overnight. 
The plasmids were isolated from each 50 mL Falcon tube bacterial culture medium by 
using EZNA® Plasmid DNA Mini Kit I. Each plasmid and vector pTYB2 plasmid was 
double-digested with restrict enzymes NdeI and XhoI. The double-digestion-products 
with PCR product of ATR cDNA fragment (A359-N484) and GeneRuler 1kb DNA 
ladder maker were separated by agarose gel electrophoresis in different wells of a 1.2 % 
agarose gel. If the small piece of the double-digestion products is the same size as the 
PCR product of ATR cDNA fragment, the plasmid was considered as a candidate 
plasmid pTYB2-ATR (A359-N484). Two candidate plasmids pTYB2-ATR (A359-N484) 
was sent out for DNA sequencing by T7 universal primer. 
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Plasmid Site-Directed Mutagenesis 
Plasmid site-directed mutagenesis was generated by following the protocol of In-
Fusion HD Cloning Kit from Clontech Laboratories.  
The In-Fusion Enzyme from the kit fuses PCR-generated DNA sequences 
efficiently and precisely by recognizing a 15 by overlap at their ends. The site-directed 
mutagenesis sites are included in 15 bp overlap. 
The PCR primers were designed as follows: ① Every In-Fusion primer must have 
two characteristics: the 5’ end of the primer must contain 15 bases that are homologous to 
15 bases at one end of the DNA fragment to which it will be joined. The 3’ end of the 
primer must contain sequence that is specific to the target gene.  ② The 3’ portion of 
each primer should: be gene-specific; be between 18-25 bases in length, and have a GC-
content between 40-60 %; have a melting temperature (Tm) between 58-65°C and the Tm 
difference between the forward and reverse primers should be ≤ 4°C.  
PCR reaction mix was prepared as follows (25 μL PCR mix per reaction): 
ddH2O                                                                                                                          9.5 μL  
5 μM Forward Primer                                                                                                    2 μL 
5 μM Reverse Primer                                                                                                     2 μL 
PARP1 cDNA Template Plasmid (pcDNA3.1-hygro-PARP1-Myc-6His) 1 ng/μL      1 μL 
CloneAmp HiFi PCR Premix                                                                                    12.5 μL 
Thermo-cycled with the following condition: 
                             98°C     10 sec 
35 cycles              55°C     15 sec 
                             72°C     42.5 sec (5 sec/kb of plasmid length) 
               Hold at 4°C      
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Cloning Enhancer Treatment. The treatment is used to digest the PARP1 cDNA 
template plasmid used in the PCR reaction to avoid the PARP1 wild type (WT) colonies 
on the antibiotic selective LB agar plates. The cloning enhancer treatment reaction mix 
was prepared as follows (7 μL per reaction): 
PCR reaction mix          5 μL 
Cloning Enhancer          2 μL 
The reaction mix was incubated in a PCR thermal cycler at 37°C for 15 min 
followed by 80°C for 15 min.  
In-Fusion Cloning Procedure. The reaction mixture was prepared as follows (10 
μL per reaction): 
ddH2O                                                         6 μL 
Cloning Enhancer-treated fragments          2 μL 
5 X In-Fusion HD Enzyme Premix            2 μL 
The reaction mix was incubated in a PCR thermal cycler at 50°C for 15 min 
followed by 4°C hold or put on ice. 
5 μL of the In-Fusion Cloning Procedure mix was used for bacterial 
transformation to 50 μL Stellar Competent Cells provided by the kit.  
The LB-ampicillin agar plates covered with 100 µL of transformed bacteria were 
placed in incubator at 37°C for 17-19 hrs. Next day, colonies were picked for plasmids 
purification and agarose gel electrophoresis was employed to select the candidate site-
directed mutagenesis plasmids. If the site-directed mutagenesis plasmids were the same 
size of wild type plasmid, they were sent out later for DNA sequencing with appropriate 
sequencing primers.  
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Table 8: List of plasmids 
Plasmids that were used as the site-directed mutagenesis template 
Mammalian expression plasmid pcDNA3.1-hygro-PARP1-Myc-6His (Gift from Dr. 
Saraswati Sukumar) 
Plasmids that were generated by site-directed mutagenesis 
pcDNA3.1-hygro-PARP1-S179A-Myc-6His 
pcDNA3.1-hygro-PARP1-T325A-Myc-6His 
pcDNA3.1-hygro-PARP1-T368A-Myc-6His 
pcDNA3.1-hygro-PARP1-S721A-Myc-6His 
pcDNA3.1-hygro-PARP1-S727A-Myc-6His 
pcDNA3.1-hygro-PARP1-S874A-Myc-6His 
pcDNA3.1-hygro-PARP1-S911A-Myc-6His 
pcDNA3.1-hygro-PARP1-E988K-Myc-6His 
pcDNA3.1-hygro-PARP1-E988Q-Myc-6His 
pcDNA3.1-hygro-PARP1-D968N-Myc-6His 
pcDNA3.1-hygro-PARP1-D965N D968N-Myc-6His 
pcDNA3.1-hygro-PARP1-∆CaBS-Myc-6His 
 
 
Table 9: List of primers for site-directed plasmid mutagenesis and cDNA fragment 
subcloning 
Primers that were used for site-directed mutagenesis 
PARP-1-S179A-F: 5’- GCGGCTCAGCTCAAGGGCTTCAGCCTCCTTGCTAC -3’ 
PARP-1-S179A-R: 5’- CTTGAGCTGAGCCGCACTGTACTCGGGCCGGAAAC-3’ 
PARP-1-T325A-F: 5’- GTC AAG GCA CAG ACA CCC AAC -3’ 
PARP-1-T325A-R: 5’ - TGT CTG TGC CTT GAC CAT ACA CTT G -3’ 
PARP1-T368A-F: 5'- GCCGCGCCTCCGCCCTCCACAGCCTCGGCTCCTGCT -3' 
PARP1-T368A-R: 5'- GGGCGGAGGCGCGGCCGCCACGGAGGCGCTGGTT -3' 
PARP-1-S721A-F: 
5’- GCGGTGGCTCAGGGCAGCAGCGACTCTCAGATCCTGGAT -3’ 
PARP-1-S721A-R: 
5’- GCCCTGAGCCACCGCCTGCTGGACCTCACTGAGGATGGA-3’ 
PARP-1-S727A-F: 5’- CGA CGC TCA GAT CCT GGA TCT -3’ 
PARP-1-S727A-R: 5’- AGG ATC TGA GCG TCG CTG CT -3’ 
PARP-1-S874A-F: 5’- GGA TCC TGG CTC AGG GTC TT -3’ 
PARP-1-S874A-R: 5’- CCT GAG CCA GGA TCC CAG CAA A -3’ 
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Table 9 (continued) 
PARP-1-S911A-F: 5’- ACT GCC ATA CGG CTC AGG GAG A -3’ 
PARP-1-S911A-R: 5’- GAG CCG TAT GGC AGT AGT TGG C -3’ 
PARP1-E988K-F: 5’-TATAACAAGTACATTGTCTATGATATTGCTCAGG-3’ 
PARP1-E988K-R: 5’-AATGTACTTGTTATATAGTAGAGAGGTGTCATTC-3’ 
PARP1-E988Q-F: 5’-TATAACCAGTACATTGTCTATGATATTGCTCAGG-3’ 
PARP1-E988Q-R: 5’-AATGTACTGGTTATATAGTAGAGAGGTGTCATTC-3’ 
PARP1-D968N-F:  
5’- CTGGATGGTGTAAACGTTCCTCTTGGGACCGGGATTTC -3’ 
PARP1-D968N-R: 5’-
 GTTTACACCATCCAGACTAATGTTAGCTGAAGGATCAGGG -3’ 
PARP1-D965ND968N-F:  
5’ - CTGAATGGTGTAAACGTTCCTCTTGGGACCGGGATTTC -3’ 
PARP1-D965ND968N-R: 
5’- GTTTACACCATTCAGACTAATGTTAGCTGAAGGATCAGGG -3’ 
PARP1-∆CaBS-F:  
5’- GGCAAAACTACCCCTGTTCCTCTTGGGACCGGGATTTC -3’ 
PARP1-∆CaBS-R:  
5’- AGGGGTAGTTTTGCCCAAACCTTTGACACTGTGCTTGC -3’ 
PARP1-D968N-F:  
5’- CTGGATGGTGTAAACGTTCCTCTTGGGACCGGGATTTC -3’ 
PARP1-D968N-R: 5’-
 GTTTACACCATCCAGACTAATGTTAGCTGAAGGATCAGGG -3’ 
PARP1-D965ND968N-F:  
5’ - CTGAATGGTGTAAACGTTCCTCTTGGGACCGGGATTTC -3’ 
PARP1-D965ND968N-R: 
5’- GTTTACACCATTCAGACTAATGTTAGCTGAAGGATCAGGG -3’ 
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Table 10: List of primers for plasmid sequencing 
DNA sequencing primers 
Primer for sequencing pcDNA3.1-hygro-PARP1-S179A-Myc-6His and pcDNA3.1-
hygro-PARP1-T325A-Myc-6His: 
PARP1-565-F: 5’-ATAGAAAAGGGCCAGGTGCG-3’ 
Primer for sequencing pcDNA3.1-hygro-PARP1-T368A-Myc-6His: 
PARP1-1061-F: 5'- AATGCTCGGGTCAGCTGGTCT-3' 
Primer for sequencing pcDNA3.1-hygro-PARP1-S721A-Myc-6His and pcDNA3.1-
hygro-PARP1-S727A-Myc-6His: 
PARP1-2169-F: 5’-CAAGCCAGTTCAGGACCTCA-3’ 
Primer for sequencing pcDNA3.1-hygro-PARP1-S874 and pcDNA3.1-hygro-PARP1-
S911A-Myc-6His: 
PARP1-2636-F: 5’-ATGCAACCACACACAATGCG-3’ 
Primer for sequencing pcDNA3.1-hygro-PARP1-D968N-Myc-6His, pcDNA3.1-hygro-
PARP1-D965ND968N-Myc-6His, pcDNA3.1-hygro-PARP1-∆CaBS-Myc-6His, 
pcDNA3.1-hygro-PARP1-E988K-Myc-6His and pcDNA3.1-hygro-PARP1-E988Q-
Myc-6His: 
PARP1-3214-R: 5’-ACCACAGGGAGGTCTTAA-3’ 
 
Plasmid Transfection of Mammalian Cells 
Transient Transfections: 
jetPEI DNA transfection reagent was used and followed the DNA transient 
transfection protocol for adherent cells. Briefly, for transfection in 24-well plates, cells 
were seeded in the plates 24 hours prior to transfection. The number (variable of different 
cell lines) of cells seeded enabled to 50-70 % confluency at the time of transfection next 
day. Changed the media next day before performing the experiment and added 1 mL of 
media per well. Per one well of 24-well plate, diluted 1 μg of DNA in 150 mM NaCl to a 
final volume of 50 μL in one 1.5 mL micro-centrifuge tube. Vortexed gently (4000rpm 
for 10 seconds) and spun down briefly to allow the liquid concentrating at the bottom of 
the tube. Per well, diluted 2 μL of jetPEI reagent in 150 mM NaCl to a final volume of 50 
μL in another 1.5 mL micro-centrifuge tube. Vortexed gently and spun down briefly. 
50 
 
Added the 50 μL jetPEI solution to the 50 μL DNA solution all at once. Vortexed the 
solution immediately and spun down briefly. Incubated for 15 to 30 min at room 
temperature. Per well, added the 100 μL jetPEI/DNA mix drop-wise to the cells in 1 mL 
of serum-containing medium and evenly mixed by gently swirling the plate. Returned the 
plates to the cell culture incubator. 48 hours later, transfected cells are allowed for the 
following planned experiment assays. 
Stable Transfection:  
The transfection was performed in 6-well plates, 60 mm or 100 mm dishes. The 
protocol was modified from the jetPEI stable transfection protocol. Briefly, performed 
the transient transfection as described above. Started antibiotic selection 48 hours after 
transfection dependent on the antibiotic gene that plasmid contained. Maintained 
antibiotic selection for 14 days by replacing the selective medium every 3 or 4 days. 
Isolated large (500-1,000 cells), healthy colonies using sterile 10 μL micropipette tips or 
toothpicks, and continued to maintain cultures in medium containing the appropriate 
antibiotic. Transferred single cells from resistant colonies into the wells of 96-well plates 
to confirm that they can yield antibiotic-resistant colonies.  
 
siRNA-Directed Protein Knockdown in Cells 
INTERFERin siRNA transfection reagent was used and followed the 
INTERFERin siRNA transfection protocol for adherent cells. Briefly, for siRNA 
transfection in 24-well plates, cells were seeded in each well of 24-well plates 24 hours 
prior to transfection. The number (variable of different cell lines) of cells seeded enabled 
to 30-50 % confluency at the time of transfection next day. Changed the media next day 
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before performing the experiment and added 500 μL of media per well. Per well, 10 μM 
of siRNA was diluted in 100 μL of serum-free medium in one 1.5 mL micro-centrifuge 
tube. Vortexed gently (4000 rpm for 10 seconds) and spun down briefly to allow the 
liquid concentrating at the bottom of the tube. Per well, added 3 μL of INTERFERin 
reagent into siRNA solution. Vortexed gently, spun down and incubated 10 minutes at 
room temperature. Per well, added transfection mix to the cells in serum containing 
medium and gently swirling the plate for 10 seconds. Returned the plates to the cell 
culture incubator. 72 hours later, transfected cells are allowed for the following planned 
experiment assays.  
 
 
Subcellular Fraction Preparation 
Subcellular fractionation was performed using the ProteoJETTM cytoplasmic and 
nuclear protein extraction kit (Fermentas) by following the protocol of the kit for 
adherent cells. Briefly, cells were harvested by scraping or trypsinized from the bottom of 
the dishes where cells go on. Cells were pelleted by centrifugation at 4°C with 10,000 
relative centrifugal force (rcf) for 10 seconds. Estimated the packed cell volume. 10 
volumes of cell lysis buffer (with protease inhibitors and DTT) were added to 1 volume 
of packed cells. Pipetted up and down several times to suspend the cell pellet. Placed the 
tube with cellular lysis suspension on ice for 10 minutes and flipped the bottom of the 
tube several times after the tube was placed on ice for 5 minutes. Separated the 
cytoplasmic fraction from nuclei by centrifugation at 500 X g for 7 minutes at 4°C. 
Carefully remove the supernatant to a new tube pre-cooled on ice. Set the nuclear pellet 
on ice. Cytoplasmic protein extract was cleared by centrifugation at 13,000 X rpm for 15 
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min at 4°C. Transferred the supernatant to a new tube marked as cytoplasmic fraction 
(CyF). Nuclei was washed twice as follows: adding 500 μL of the nuclei washing buffer 
(with protease inhibitors and DTT) to nuclear pellet followed by pipetting up and down 
several times; pelleted the nuclei by centrifugation at 500 X g for 7 minutes at 4°C and 
discarded the supernatant. Added 10 volumes of ice-cold nuclei storage buffer (with 
protease inhibitors and DTT) to the nuclear pellet. Pipetted up and down several times to 
suspend the nuclear pellet. 1/10 volume of the nuclei lysis reagent was added to nuclei 
suspension. Vortexed briefly and rotated for 15 minutes at 4°C (900-1200 rpm) followed 
by placed on ice for 20 minutes. 
Table 11: Volume of 0.1 M DTT added into each lysis buffer (0.1 M DTT was added to 
the provided reagents fresh before use) 
Buffer Required Volume Per Prep. 0.1 M DTT 
Cell Lysis Buffer 200 μL 2 μL 
Nuclei Washing Buffer 1000 μL 30 μL 
Nuclei Storage Buffer 150 μL 7.5 μL 
 
 
Protein Concentration Measurement 
Protein concentration was measured with Pierce 660 nm Protein Assay Reagent 
by following the microplate procedure protocol of the reagent. Briefly, prepared the 50 
ng/μL, 100 ng/μL, 200 ng/μL and 400 ng/μL standard by diluting 2,000 ng/μL BSA 
standard with ddH2O. Pipetted 10 μL of each triplicate of standard and ddH2O into wells 
of 96-well plate. Pipetted 2 μL of protein samples into wells of 96-well plate. Each 
protein sample is triplicate. The corresponding buffer that protein samples dissolved in as 
mock. Added 8 μL of ddH2O to each well containing 2 μL samples or buffer to ensure the 
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total volume of each well was 10 μL. Added 150 μL of the protein assay reagent to each 
well. Covered the plate and mixed on a plate shaker at medium speed for 1 minute. 
Incubated at room temperature for 5 minutes. Measured the absorbance of the standards 
and proteins samples at 660 nM. A standard curve was built by plotting the average 
blank-corrected 660 nM measurement of each BSA standard with unit of ng/μL. Used the 
standard curve to determine the protein concentration of each protein sample. 
 
 
Immunodetection (Western Blot) 
After the procedure of protein blotting, PVDF membrane was taken out and used 
in an immunodetection procedure to reveal specific/expected proteins. Briefly, placed the 
PVDF membrane into blocking solution (5% of non-fat milk in 1X Tris-buffered saline 
tween-20 (TBST) buffer) on a rocker gently for 1 hour at room temperature or overnight 
at 4°C. A sufficient volume of blocking buffer was used to keep the membrane fully 
covered. Rinsed the membrane briefly in 1 X TBST buffer. Appropriately diluted primary 
antibody in 1 X TBST buffer according to each antibody, usually from 1:100 to 1:3000. 
Incubated the membrane with sufficient volume of primary antibody buffer to keep the 
membrane fully covered on a rocker gently shaking. Incubated for 2 hours at room 
temperature or overnight at 4°C. Rinsed the membrane in 1 X TBST buffer (3 X 10 min) 
on a shaker gently in a sufficient volume to keep the membrane fully covered. Diluted 
(1:5000) horseradish peroxidase (HRP)-conjugated secondary antibody in 1 X TBST 
buffer. Incubated the membrane in a sufficient volume of the secondary antibody buffer 
to keep the membrane well covered for 1 hour at room temperature on a rocker gently 
shaking. Rinsed the membrane in 1 X TBST buffer (2 X 10 min) on a shaker gently 
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shaking. Drained excess 1 X TBST buffer form the membrane and added appropriate 
volume of HRP substrate solution (from SuperSignal® West Pico chemiluminescent 
substrate kit) on the surface of the membrane. Incubated the membrane with the substrate 
solution for 5 minute, kept the membrane from light. Removed the membrane from the 
substrate solution and drained the excess reagent. Exposed the membrane to Fuji imagine 
system. 
20 X Tris-buffered saline (TBS) Buffer Stock (1L) 
60 g Tris base 
160 g NaCl 
4 g KCL 
Added ddH2O to 1L 
Final working (1 X TBST) buffer concentration: 50 mM Tris-HCl, 150 mM NaCl, 2.7 
mM KCl, 0.05 % Tween 20 
 
Blocking Buffer: 5 % non-fat milk dissolved in 1 X TBST buffer 
 
 
Coomassie Blue Staining 
Rinsed the SDS-polyacrylamide gel in ddH2O briefly after protein blotting. 
Sufficient volume of different buffers mentioned in Table 12 were used to keep the gel 
fully covered. Fixed the gel in fixing solution for 1 hour at room temperature shaking 
gently on a shaker. Stained the gel in staining solution for 20 minutes at room 
temperature with gentle agitation. Destained the gel in destaining solution, changed the 
solution several times, till the background of the gel is fully destained. Stored the 
destained gel in storage solution in 4°C in super clean container. The recipe of solutions 
used in coomassie blue staining is shown in table 12. 
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Table 12. Recipe of solutions used in coomassie blue staining 
 Coomassie Brilliant 
Blue 250  
Methanol Glacial Acetic Acid 
 Percentage of component in different solution (%) 
Fixing solution 0 50 10 
Staining solution 0.1 50 10 
Destaining solution 0 40 10 
Storage solution 0 0 5 
 
 
Immuno-Fluorescence (IF) of Nuclear Proteins 
Placed one autoclaved cover slip (20 mm diameter) into a 35 mm X 10 mm cell 
culture dish and seeded cells into the dish. Incubated the cells overnight in the cell culture 
incubator. Treated cells next day according to the experimental plan (i.e. ionomycin 
treatment, drug treatment, UV treatment, etc.). Following the treatment and appropriate 
incubation time, placed the cell culture dish on ice. Filled one well of a 6-well plate with 
ice-cold 1 X PBS. Moved the cover slip on which cells were seeded to the well. Rinsed 
the cells with ice-cold 1 X PBS briefly twice and discarded the PBS. Incubated the cover 
slips in the culture dish in 100 % methanol (-20°C) for 10 minutes at -20°C to fix cells 
seeded onto the cover slip. Removed the methanol and rinsed the cells with ice-cold 1 X 
PBS briefly thrice and discarded the PBS. Blocked the cells with 1 X TBST containing 
15 % FBS for 30-60 minute at room temperature on a shaker gently shaking. Discarded 
the blocking buffer and rinsed the cells briefly in 1 X TBST. Diluted the primary 
antibody in sufficient 1 X TBST containing 15 % FBS as there would be 20 μL of diluted 
primary antibody solution for each cover slip. The dilution factors should be determined 
for each antibody used since it varied among different antibodies. Pipetted 20 μL of the 
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diluted primary antibody solution onto a section of parafilm. Removed the cover slip 
from 1 X TBST and removed the excess buffer from the cover slip by touching one edge 
of the clover slip to a Kim-wipe. Carefully and gently placed the cover slip cell-side 
down onto the drop of the diluted primary antibody solution avoiding air buffer between 
the cover slip and the antibody solution. Repeated for each cover slip. Placed the parafilm 
with cover slips on it in a humidifying chamber and incubated for 1 hour at room 
temperature. Removed the cover slips from the parafilm gently with forceps and placed 
them in the cover slip rack. Rinsed the cover slips in 1 X TBST (3 X 10 minutes). For 
fluorescent-conjugated secondary antibody incubation, repeated the processes of primary 
antibody incubation and the following cover slips rinsing. Light needed to be avoided for 
the whole processes of secondary antibody incubation and following processes. Dropped 
one drop (~ 15 μL) of DAPI staining solution on a cover slide. Rinsed the cover slip with 
ddH2O once and removed the excess ddH2O from the cover slip by touching one edge of 
the cover slip to a Kim-wipe. Carefully and gently placed the cover slip cell-side down on 
to the drop of DAPI staining solution avoiding air buffer between the cover slip and the 
DAPI staining solution. Repeated for each slip. Waiting for 10 minutes at room 
temperature. The cells were ready for taking the immunofluorescent pictures via EVOS 
immunofluorescent microscope. 
 
Immunoprecipitation (IP) of Nuclear Extract for Mass Spectrometry or Co-IP of Nuclear 
Extract for Protein Interaction Analysis 
PierceTM Protein G agarose beads were used for IP. Briefly, cytoplasmic extract 
was performed followed the subcellular fraction preparation protocol as mentioned above. 
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The washed nuclei of the cells were lysed in ice-cold buffer AB in a 1.5 mL micro-
centrifuge tube for 15 minutes on ice or on a rotator at 4°C. Nuclear lysate was cleared by 
centrifugation at 13,000 rpm for 10 min at 4°C. Gently took the tube out from the 
centrifuge and placed on ice. Transferred the supernatant into another pre-ice-cold 1.5 
mL micro-centrifuge tube. Added appropriate volume of ice-cold buffer AB to the 1.5 
mL micro-centrifuge tube to ensure the total nuclei lysate for each tube is 500 μL. Added 
1 μL of anti-PARP1 antibody to each tube. Incubated the mix overnight at 4°C on a 
rotator. Added 50 μL of Protein G agarose slurry to the antigen-antibody complex next 
day. Incubated the reaction for 2 hours at room temperature on a rotator. Centrifuge the 
mix for 20 seconds at 2,500 rcf at room temperature. Transferred the supernatant to 
another 1.5 mL micro-centrifuge tube and stored it at 4°C. Added 500 μL ice-cold Co-IP 
washing buffer into the tube with the Protein G agarose beads and gently mixed it well 
with the beads. Centrifuged tube for 20 seconds at 2,500 rcf and discarded the 
supernatant. Repeated this step two more times. Added 60 μL of 2 X SDS loading buffer 
to each 1.5 mL micro-centrifuge tube containing Protein G agarose beads. Mixed the 
buffer with beads well. Put the tubes in the wells of a dry block to heat the SDS loading 
buffer/protein samples mix for 3-5 minutes at 100°C to denature the proteins. The 
samples were loaded on 3-8 % gradient gel followed by gel electrophoresis. After the 
coomassie blue staining, the destained gel was put in a super-clean plasmid bag with a 
little bit ddH2O in it to keep the gel wet. The gel pack was sent out for mass spectrometry. 
Buffer AB: 
140 mM NaCl 
50 mM Tris-HCl pH 7.8 
10 % Glycerol  
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1 % NP-40 
1 mM EDTA 
Protease and Phosphatase Inhibitors added fresh before use 
Co-IP (Co-immunoprecipitation) Wash Buffer: 
140 mM NaCl 
50 mM Tris-HCl pH 7.6 
10 % Glycerol 
0.2 % Tween 20 
1 mM EDTA 
 
Recombinant FLAG-ATR Protein Purification 
Human kidney HEK293T cells, mammalian expression plasmid pcDNA3.1-
FLAG-ATR, PierceTM Protein G Agarose beads and anti-FLAG M2 mouse antibody were 
used for recombinant FLAG-ATR protein purification. Briefly, HEK293T cells were 
seeded overnight ahead of pcDNA3.1-FLAG-ATR plasmid transfection. 4 X 106 cells 
were seeded in each 150-mm dish of 8 dishes. Next day, removed the old media and 
added 15 mL 37°C-warmed fresh cell culture media to each dish before plasmid 
transfection. 20 μg of pcDNA3.1-FLAG-ATR plasmids were used for transfection of one 
dish of HEK293T cells. After 48 hours transfection, 8 dishes were put on ice. Discarded 
the media and washed the cells with ice-cold 1 X PBS twice gently. Scrapped the cells in 
1 X PBS on ice and collected cells by centrifugation for 5 minutes at 5,000 rcf at 4°C. 
Lysed the cell pellets in 15 mL ice-cold cellular lysis buffer for 20 minutes at 4°C on a 
rotator. Completed the following steps in 4°C cold room. Clarified the cell lysate by 
centrifugation at 10,000 rcf for 10 minutes at 4°C. Transferred the clarified lysate 
(supernatant) into two Falcon 15 mL conical centrifuge tubes, 7.5 mL per tube. Added 15 
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μL of anti-FLAG M2 antibody to each tube of cell lysate. The antibody dilution factor 
was 1:500. Rotated the lysate/antibody mix for 2-4 hours. Added 150 μL of Protein G 
agarose slurry to each tube of lysate/antibody mix and rotated overnight. The FLAG-
ATR-bound beads were washed gently by wash buffer A briefly twice, high salt wash 
buffer A for 3 minutes on a rotator and wash buffer A briefly thrice. Transferred the 
FLAG-ATR-bound beads to a pre-ice-cold 1.5 mL micro-centrifuge tube. Recombinant 
FLAG-ATR protein was eluted from beads with 0.5 mL elution buffer overnight on a 
rotator. Next day, measured the concentration of eluted recombinant FLAG-ATR protein 
by following the microplate procedure protocol of Pierce 660 nm Protein Assay Reagent. 
If the protein concentration above 100 ng/μL, aliquoted the recombinant FLAG-ATR in 
pre-ice-cold 1.5 mL micro-centrifuge tubes, 10 μL/tube. If the protein concentration is 
below 100 ng/μL, concentrated the protein by dialysis in elution buffer containing 50 % 
glycerol lacking FLAG peptide overnight. Then measured the concentration of FLAG-
ATR and aliquoted them with 5-10 μL/tube. Stored the recombinant FLAG-ATR protein 
aliquots in -80°C. Coomassie blue staining and western blot was applied to confirm the 
purification of the recombinant FLAG-ATR protein and the purified FLAG-ATR protein 
respectively.  
Cellular Lysis Buffer: 
50 mM HEPES-KOH, pH 7.4 
150 mM NaCl 
1 mM EDTA 
1 % Triton X-100 
1 X Protease & Phosphatase inhibitor was added fresh before use 
Wash Buffer A: 
50 mM HEPES-KOH, pH 7.4 
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150 mM NaCl 
1 mM EDTA 
0.05 % NP-40 
High Salt Buffer A: 
50 mM HEPES-KOH, pH 7.4 
1 M NaCl 
1 mM EDTA 
0.05 % NP-40 
Elution Buffer: 
50 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 
10 % Glycerol, 
200 μg/mL FLAG peptide was added fresh before use 
1 mM DTT was added fresh before use 
1 X Protease & Phosphatase inhibitor was added fresh before use 
Dialysis Buffer: 
50 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 
50 % Glycerol, 
1 mM DTT was added fresh before use 
 
Recombinant Glutathione S-Transferase (GST)-Pin1 Protein Purification 
GST-Pin1 plasmid is a bacterial expression plasmid and was transformed into 
BL21 (DE3) E.coli cells for protein expression and purification. Briefly, a sterile 
cryogenic storage vial containing the glycerol bacterial stock of GST-Pin1 transformed 
BL21 (DE3) E.coli cells stored in -80ºC ultralow temperature freezer was taken out and 
put on ice. Using a 10 μL micropipette tip to scrape a small piece of frozen glycerol 
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bacterial stock. Dropped the tip into 50 mL LB broth with 100 μg/mL ampicillin. 
Incubated overnight at 37°C with 220 rpm. Next day, transferred 40 mL of the overnight 
bacteria cell culture into 2 L LB broth with 100 μg/mL ampicillin. Incubated at 37°C 
incubator with shaking at 220 rpm. Checked the OD600 of the cell culture media (LB 
broth) and only LB buffer every one or two hours. Reduced the incubation temperature to 
30°C when the OD600 of the cell culture media reached ~0.5. Adding IPTG into LB broth 
when the OD600 of LB broth reached 0.6. The final concentration of IPTG is 1 mM. 
Incubated the cell culture at 30°C incubator with shaking at 220 rpm for 5 hours. Harvest 
cells by centrifugation for 10 minutes at 6,000 rpm at 4°C. Discarded the cell culture 
media, and the cell pellet could be frozen at -80°C ultralow temperature freezer for 
completing next steps next day. Re-suspend the cell pellet in 20 mL ice-cold LKB buffer 
on ice in one Falcon 50 conical centrifuge tube. Lysed the bacterial cells with sonication 
by using the micro-tip horn on ice. One cycle of sonication was sonicating for 10 second 
at 25 % intensity, followed by 20 seconds of rest. Repeated 8 cycles of sonication. 
Clarified extracts by centrifugation for 10 minutes at 12,000 rpm at 4°C. Transferred the 
clarified supernatant evenly into two Falcon 15 mL centrifuge tubes. Completed the 
following steps in 4°C cold room. Total 200 μL glutathione agarose beads were used to 
rotate with the bacterial cell extracts in 20 mL LKB buffer overnight. The GST-Pin1-
bound beads were washed with LKB buffer twice gently followed by centrifugation for 
20 seconds at 2,500 rpm and discarded the supernatant. The GST-Pin1-bound beads were 
eluted with elution buffer for overnight. The eluted fraction was dialyzed with elution 
buffer contain 50 % glycerol overnight. The dialyzed GST-Pin1 protein was aliquoted 
into 1.5 mL micro-centrifuge tubes with 20 μL per tube. Stored the aliquots at -80ºC 
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ultralow temperature freezer. Measured the concentration of dialyze GST-Pin1 protein by 
following the microplate procedure protocol of Pierce 660 nm Protein Assay Reagent. 
Coomassie blue staining and western blot was applied to checked the purification of the 
recombinant GST-Pin1 protein and confirm the purified GST-Pin1 protein respectively. 
LKB buffer: 
  25 mM Tris-HCl, pH 7.5 
  100 mM NaCl 
  1 mM EDTA 
  1 mM EGTA 
  0.5 % NP-40 
  25 mM β-glycerophosphate 
  50 μg/ml phenylmethylsulfony fluoride 
  10 μg/ml leupeptin, 10 μg/ml aprotinin 
  1 mM DTT was added fresh before use 
  Protease and phosphatase inhibitors were added fresh before use 
Elute Buffer 1: 
  25 mM Tris-HCl, pH 7.5, 
  1 mM EDTA 
  1 mM DTT was added fresh before use    
Elute Buffer 2: 
  25 mM Tris-HCl, pH 7.5, 
  1 mM EDTA 
  1 mM DTT was added fresh before use 
  10 mM reduced glutathione 
Dialysis Buffer: 
  25 mM Tris-HCl, pH 7.5, 
  1 mM EDTA 
  50 % Glycerol 
  1 mM DTT was added fresh before use 
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In-vitro PARylation Assay Using ATR, PARP1, Ca2+ and NAD+, [32P] 
The PARylation reaction was performed as described in papers published in 2008 
and 2014 (Kedar et al. 2008; Fischer et al. 2014). Briefly, purified PARP1 (20 nM) 
purchased from ThermoFisher Scientific, purified ATR (40 nM) from out lab alone, or a 
mixture of proteins containing PARP1 (20 nM) or Histone H1 (30 nM) (which are 
mentioned in Figure 13A), were incubated in a PARylation reaction buffer (PRB) in 1.5 
mL micro-centrifuge tubes. The final volume of the reaction mixture was 40 μL. The 
reaction was started by adding 200 μM NAD+,[32P]. Incubated the reaction mix for 30 
minutes in the water bath of 30°C. Mixed the reaction mixture several times by gently 
tapping the bottom of the 1.5 micro-centrifuge tubes during incubation time period. 
PRB buffer: 
100 mM Tris-HCl pH 7.8 
10 mM MgCl2 
1 mM DTT 
25 μg/mL activated DNA oligo 
200 μM NAD+   
40 μL reaction mix 
40 nM ATR (0.6 μg) 
20 nM PARP1 (0.1 μg) 
30 nM Histone H1 (0.05 μg) 
 
Trypan Blue Exclusion Assay 
Trypan blue exclusion assay was used to determine cell viability. Dead cells with 
broken cell membrane took up trypan blue dye. % viable cells = [1.0 – (number of blue 
cells ÷ number of total cells)] X 100. Added 0.1 mL of 0.4 % trypan blue stock solution 
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to 1 mL of cell suspension. Counted the number of blue cells and the total number of 
cells, within the grids of the hemocytometer, under a light microscope.  
 
CellTiter Blue Cell Viability Assay 
CellTiter Blue Cell Viability Assay is based on the ability of living cells to 
convert a redox dye (resazurin) into a fluorescent end product (resorufin). The procedure 
was following the protocol of the CellTiter-Blue Reagent from Promega. Briefly, cells 
were seeded in wells of 96-well microplate one day ahead of the assay. Next day, added 
reagent directly to cells in culture, 5 μL per each well. Put the plate back into 37°C cell 
culture incubator and incubated for 2 hours. The fluorescence [560Ex/590Em] was 
recorded by using a fluorescent microplate reader.  
 
LDH Release Assay 
The assay measures the lactate dehydrogenase (LDH) released into culture 
supernatants. The released LDH converts a tetrazolium salt (INT) into a red formazan 
product. The amount of color formed is proportional to the number of lysed/dead cells. 
Briefly, cells were seeded in wells of 96-well microplate one day ahead of the assay. 
Next day, following experimental treatment, supernatant samples were transferred to 
another 96-well plate and an equal volume (50 μL) of CytoTox 96 Reagent is added to 
each well. Lysis Solution was added as 1:10 dilution to some wells for 45 minutes to lyse 
all cells as positive control. Incubated the mix for 30 minutes at room temperature 
followed by adding 50 μL of Stop Solution in each well. Incubated the mix for 15 
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minutes at room temperature. The absorbance signal was measured at 490 nM in a 
microplate reader.  
 
Propidium Iodide (PI) Staining  
PI is a fluorescent membrane-impermeable dye that stains nuclei by intercalating 
between the stacked bases of nuclei acids. It was used to determine the loss of cell 
membrane integrity, as it enters cells if the plasma membrane becomes permeable. While 
Hoechst 33343 is a cell membrane permeable nuclear counterstain that emits blue 
fluorescence when bound to dsDNA. Both dyes were used at the same time in the 
experiment to determine the ionomycin-induced percentage of necrotic cell death. Briefly, 
after ionomycin treatment, discarded the treated media and washed the cells with 37°C-
warmed 1 X PBS twice gently. Dilute both PI and Hoechst 33342 into 37°C-warmed 1 X 
PBS with dilution factor as 1:200. Added PBS containing both dyes to each well to cover 
the cells and incubated for 10 minute at 37°C cell culture incubator. Discarded the 
staining mix and washed the cells with 37°C pre-warmed 1 X PBS twice gently. Added 
pre-warmed PBS into each well to cover the cells fully. Images were taken with EVOS 
fluorescent microscope. 
 
Intracellular Calcium Concentration Measurement 
HCT116 ATR+/+ and ATRflox/- (ATR-proficient and -deficient) cells were grown 
on glass coverslips and then loaded with Fura2 for 30 min at room temperature. Cells 
were washed with PBS to remove excess Fura2 and then transferred to an acrylic 
chamber on the microscope stage. Fluorescence measurements were recorded as soon as 
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cells were placed on the stage (0 min). After 10 min. the normal media was removed and 
replaced with media containing calcium (10 mM) and ionomycin (10 μM). Following 10 
min incubation, the media was removed and replaced with media lacking calcium. 
Recording proceeded for another 10 min after which recording was terminated. 
Fluorescence was measured with an imaging system composed of a filter wheel and a 
Basler A311F VGA camera connected to an Olympus IX71 inverted microscope. 
Automated In Cyte2 software controlled data collection and the filter wheel.  Calcium 
concentration was measured by interpolation from a standard curve generated by 
calibration buffer kit #2 (Molecular Probes) and Fura2/K5-salt. Background fluorescence 
was corrected for, and the ratio of the fluorescence at excitation wavelengths (F340/F380) 
was monitored in 30-40 cells. 
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CHAPTER 3 
RESULTS 
 
ATR Plays a Role in Suppressing the Ionomycin-Induced Cell Death 
Ionomycin, a Ca2+ ionophore, was used to induce necrosis by increasing 
intracellular Ca2+ concentration (Hermann 1978; Vaseva et al. 2012). Data of Figure 26 
shows that ionomycin treatment did induce intracellular Ca2+ concentration overload. The 
effect of ATR on ionomycin-induced cell death was assessed in different human 
fibroblasts and cancer cell lines. Human HCT 116 ATR-proficient and -deficient cells 
(ATR+/+ and ATRflox/- cells, respectively) were treated with Ca2+ ionophore ionomycin, 
followed by trypan blue exclusion assay to measure the percentage of cell death. As 
shown in Figure 10A, a significantly higher cell death was observed in the absence of 
ATR than in the presence of ATR. CellTiter-blue cell viability assay (Figure 10B) also 
showed that cells had significantly lower viability, after ionomycin treatment, in the 
absence of ATR than in the presence of ATR. The results suggest that ATR enables cells 
to resist the ionomycin-induced cell death. In addition, ATR was knocked down in 
different human cancer cells (A549 and U2OS) and fibroblast cells (A1, passage 18) 
using small interfering RNA (siRNA) specific to ATR (Figure 10C, 10D and 10E). 
Trypan blue exclusion assay showed that ionomycin treatment induced significantly more 
cell death in ATR-siRNA knockdown (siATR) cells than in siRNA control cells 
(siCTRL). High mobility group box 1 (HMGB1) is a nuclear protein bound to the 
chromatin under normal condition. HMGB1 is released into cell culture media when 
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necrosis happens (Harris and Andersson 2004; Zong and Thompson 2006; Han et al. 
2008; Cho et al. 2010). The cell-to-media release of HMGB1 is a marker of necrotic cell 
death. Western blot (WB) analysis of TCA-precipitated media protein using HMGB1 
antibody showed that significantly more HMGB1 was released into media from cells in 
the absence of ATR than from cells in the presence of ATR (Figure 10F). This result 
indicates that ATR may play a role in suppressing the ionomycin-induced necrotic cell 
death. Since ATR is well known for its regulatory role in DDR, it is of interest to 
determine whether the role that ATR plays in suppressing ionomycin-induced cell death 
is DNA damage dependent. As shown in Figure 10G, WB analysis showed that although 
the DNA strand-break marker (γH2AX) and DDR markers (p-p53 (S15) and p-Chk1 
(S345)) were detected in UV-treated cells, none of them were detected in ionomycin-
treated cells. Taken together, all above results indicate that ATR may play an anti-
necrotic role in suppressing the ionomycin-induced cell death. This anti-necrotic activity 
of ATR is likely part of cell non-DNA damage stress response (NDDR).  
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Figure 10. ATR plays a role in NDDR by suppressing the ionomycin-induced cell death. 
(A) Human ATR+/+ and ATRflox/- cells were treated with ionomycin (10 μM) for the 
indicated periods before cell death rate in percentage was measured using the trypan blue 
exclusion assay. Western blot (WB) analysis of ATR expression in ATR+/+ and ATRflox/- 
cells. (B) ATR+/+ and ATRflox/- cells were treated with ionomycin as indicated followed 
by the measurement of the loss of cell viability in percentage using the CellTiter-blue cell 
viability assay. (C, D & E) Human A549 cells, U2OS cells, or A1 fibroblast cells 
(passage 18) were transfected with siRNA specific for ATR followed by ionomycin 
treatment as indicated, then the percentage of cell death was measured by empolying 
trypan blue exclusion assay. WB analysis of ATR knockdown in cells. (F) ATR+/+ and 
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ATRflox/- cells were treated with ionomycin for 4 hours. Media proteins were precipitated 
by TCA precipitation assay. WB analysis of HMGB1 released into media as GAPDH in 
whole cell extract (WCE) as loading control. (G) A549 cells were treated either with UV-
C 40 J/m2 followed by recovery for 2 hours or with ionomcyin (10 μM) for 4 hours. WB 
analysis of WCE for the DDR marker: γH2AX (p-H2AX(S139)), p-p53(S15) and p-
Chk1(S345).  
 
 
Necrosis is the Exclusive Form of Cell Death Induced by Ionomycin 
Cell morphology-based assay was employed to analyze the cell death induced by 
ionomycin and apoptosis-inducer camptothecin (CPT). As shown in Figure 11A, 
ionomycin-induced Ca2+ overload resulted exclusively in necrotic cell death characterized 
by cellular swelling, while CPT treatment efficiently induced apoptosis as characterized 
by cellular shrinkage and the formation of apoptosis bodies (Proskuryakov et al. 2003; 
Festjens et al. 2006; Krysko et al. 2008). The quantification of data from Figure 11A 
(Figure 11B) showed that significantly more necrosis was induced by ionomycin in ATR-
deficient cells than in ATR-proficient cells. WB analysis showed that CPT treatment, not 
the ionomycin treatment, induced cleavage of caspase-3, caspase-7 and PARP1 in both 
ATR+/+ and ATRflox/- cells (Figure 11C and 11D). Since the cleavage of caspase-3, 
caspase-7 and PARP1 are the apoptotic molecular events (Kaufmann et al. 1993; 
Lazebnik et al. 1994; Boulares et al. 1999; Ha and Snyder 1999; Kitanaka and Kuchino 
1999; D’Amours et al. 2001; Bröker et al. 2005), the results further confirm that 
ionomycin-induced Ca2+ overload induces necrosis exclusively. Furthermore, ATR+/+ and 
ATRflox/- cells were pre-incubated with mock or Z-VAD-FMK (10 μM, 1 hr), a broad 
spectrum caspase inhibitor (Slee et al. 1996), followed by mock or ionomycin treatment. 
The percentage of cell death was measured using trypan blue exclusion assay. As shown 
in Figure 11E, apoptosis inhibitor Z-VAD-FMK pre-incubation did not significantly 
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affect ionomycin-induced cell death rate, in percentage, in ATR-proficient and -deficient 
cells, and there was significantly higher ionomycin-induced necrosis in the absence than 
in the presence of ATR. The results from Figure 11A-11E suggest that necrosis is the 
unique form of cell death induced by ionomycin-induced Ca2+ overload and ATR plays a 
role in suppressing the ionomycin-induced necrosis. 
Figure 11. Necrosis is the exclusive form of cell death induced by ionomycin. (A) ATR+/+ 
and ATRflox/- cells were treated with either ionomycin (10 μM, 4 hrs) or apoptosis inducer 
camptothecin (CPT) (10 μM, 24 hrs) followed by phase-contrast imaging (20 X). 
Necrosis characterized by cellular swelling and nuclear shrinkage was exclusively 
induced by ionomycin treatment. (B) Quantification of morphologic analysis in B. (C & 
D) WB analysis of the cleavage of caspase-3, caspase-7 and PARP1 in ATR+/+ and 
ATRflox/- cells treated with either ionomycin or CPT as in B. (E) ATR+/+ and ATRflox/- 
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cells were pre-incubated with apoptosis inhibitor A-VAD-FMK (10 μM, 1 hr) or mock 
treatment followed by mock or ionomycin treatment (10 μM, 4 hrs) before the percentage 
of necrotic cell death was measured using trypan blue exclusion assay.  
 
Ionomycin Treatment Hyper-Activates the Poly(ADP-ribosyl)ation (PARylation) 
Activity of PARP1 
Necrosis is characterized by bio-energetic catastrophe due to the ATP pool 
depletion induced by hyper-activation of PARP1. PARP1can hydrolyze NAD+ into NAM 
and ADPr and covalently connect the ADPr units to its protein targets or itself to form 
poly(ADP-ribose) (PAR) polymers. Hyper-activation of PARP1 leads to excessive 
consumption of NAD+ pool, which causes the ATP depletion in cells, and then induces 
necrosis. We proposed that ionomycin induces necrosis via hyper-activation of PARP1. 
A549 cells were treated with ionomycin for indicated periods (Figure 12A), followed by 
WB analysis of formation of PAR polymers using anti-PAR antibody. As shown in 
Figure 12A, ionomycin-induced formation of PAR polymers was time-dependent. Next, 
A549 cells were treated with ionomycin in the presence of PARP inhibitors, 3-ABA or 
AG-14361, followed by WB analysis of PAR polymers formation. Figure 12B and 12C 
show that inhibition of PARP suppressed the ionomycin-induced formation of PAR 
polymers. It was reported that PARP1 is responsible for about 90% of cellular PAR 
polymers formation under DNA damage (D’Amours et al. 1999; Bürkle 2005; Yelamos 
et al. 2011). It is of interest to determine whether PARP1 is responsible for the 
ionomycin-induced formation of PAR polymers or not. As shown in Figure 12D, 
compared with ionomycin-induced formation of PAR polymers in control cells, cells with 
PARP1 knockdown failed to form PAR polymers. The result indicates that PARP1 is 
responsible for the ionomycin-induced formation of PAR polymers. We further used 
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human A549 shPARP1 and shCTRL cells, a gift from Dr. Csaba Szabo and Dr. Laszlo 
Virag.  These cells are A549 cells transfected with short hairpin RNA (shRNA) specific 
to PARP1 or control shRNA (Erdélyi et al. 2009). WB analysis of PARP1 expression in 
shCTRL and shPARP1 cells is shown in Figure 12G. Immunofluorescence (IF) assay 
(Figure 12E) shows that ionomycin treatment induced formation of PAR polymers only 
in shCTRL cells, but not in shPARP1 cells. Data in Figure 12D and 12E confirm that 
PARP1 is responsible for the ionomycin-induced formation of PAR polymers. 
Furthermore, propidium iodide (PI) as a cellular membrane impermeable fluorescent dye 
was used to measure the percentage of necrotic cell death after ionomycin treatment. As 
shown in Figure 12F and 12G, there was significantly more necrosis in shPARP1 cells 
than in shCTRL cells. Figure 12H shows that PARP1 overexpression in shPARP1 cells 
sensitized cells to ionomycin-induced necrosis. The results suggest that necrosis is caused 
by ionomycin-induced hyper-activation of PARP1. In support, supplementation of NAD+ 
to media can recue A549 cells from ionomycin-induced necrosis as determined by LDH 
release assay (Figure 12I). The result supports that NAD+ pool excessive consumption by 
hyper-activated PARP1 is the cause of necrosis. Taken together, all these results suggest 
that ionomycin-induced hyper-activation of the PARylation activity of PARP1 is the 
cause of necrosis.  
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Figure 12 (continued to the next page) 
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Figure 12. Ionomycin treatment hyper-activates the PARylation activity of PARP1. (A) 
A549 cells were treated with ionomycin (10 μM) as indicated time period, followed by 
WB analysis of formation of PAR polymers using anti-PAR antibody. (B & C) A549 
cells were treated with ionomycin (10 μM, 4 hours) following pre-incubation with potent 
PARP1 inhibitor (either 3-ABA or AG14361). Formation of PAR polymers are detected 
by WB analysis using anti-PAR antibody. (D) A549 cells were transfected with siRNA 
specific for PARP1 or negative control siRNA, followed by ionomycin (10 μM) or mock-
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treatment for indicated periods. Cell lysates were analyzed by WB for PARylation using 
anti-PAR antibody. (E) Human A549 shPARP1 and shCTRL cells were treated with 
ionomycin (10 μM) or mock for 2 hours, followed by immunofluorescence staining using 
indicated antibodies. Fluorescence microscopy images were taken with 20 X objective. (F) 
shCTRL and shPARP1 cells were treated with ionomycin or ethanol as mock as 
mentioned in E, followed by PI staining. (G) Quantification of data from F and WB 
analysis of PARP1 expression in shCTRL and shPARP1 cells. (H) PARP1-overexpressed 
shPARP1 cells were treated with ionomycin or ethanol for mock, followed by trypan blue 
staining. (I) Cell culture media of A549 cells supplemented with or without NAD+ (10 
mM) for 1 hour before the ionomycin (10 μM, 2 hours) treatment, followed by 
measurement of loss of cell viability via LDH assay.  
 
 
Ionomycin Treatment Promotes Physical Interaction of ATR and PARP1 for Suppressing 
Necrosis  
Based on the results of Figures 10-12, we hypothesized that ATR plays a role in 
suppressing the ionomycin-induced hyper-activation of PARP1. Figure 13A shows that 
cells had much less ionomycin-induced PAR polymers in the presence of ATR than in the 
absence of ATR. Also, the ionomycin-induced PAR polymer formation dramatically 
increased in A549 cells pre-incubated with VE822 as shown in Figure 13B. VE822 was 
reported as an inhibitor of ATR in 2012 (Fokas et al. 2012). Figure 13A and 13B indicate 
that ATR plays a role in suppressing the ionomycin-induced PAR polymers. In addition, 
A549 cells were treated with ionomycin or ethanol (mock) followed by fractionation to 
isolate cytoplasmic fraction (CyF) and nuclear fraction (NuF). ATR immunoprecipitation 
(IP) from CyF and NuF to check how much PARP1 interact with ATR. As shown in 
Figure 13C, there is hugely increasing of PARP1 co-IPed from ATR in the NuF of 
ionomycin-treated cells than PARP1 co-IPed from ATR in the NuF of ethanol-treated 
cells. The result indicates that ionomycin treatment induces ATR-PARP1 binding. The 
same also was true in HCT116 cells as shown in Figure 13D. Alternatively, proximity 
ligation assay (PLA) technology is capable of reporting protein-protein interactions in 
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fixed cells (Gustafsdottir et al. 2005; Söderberg et al. 2008). As shown in Figure 13E, 
ATR-PARP1 complexes were found in ionomycin-treated cells rather than mock-treated 
cells. The quantification of the PLA data shows that ionomycin treatment induced ATR-
PARP1 interaction. Data from Figure 13C-13E demonstrate that ionomycin treatment 
induces ATR physical interaction with PARP1.  
Figure 13. Ionomycin treatment induces ATR physical interaction with PARP1 for 
suppressing necrosis. (A) WB analysis of PAR polymers in ATR+/+ and ATRflox/- cells 
treated with ionomycin (10 μM) as indicated using anti-PAR antibody. (B) WB analysis 
of PAR polymers in A549 cells treated with ionomycin (10 μM, 4 hrs) in the presence or 
absence of ATR inhibitor VE822 (10 μM, 1hr pre-incubation). (C) A549 cells were 
78 
 
treated with ionomycin (10 μM) for 4 hours, followed by fractionation. ATR was 
immuno-precipitated (IPed) both in cytoplasmic and nuclear fraction (CyF and NuF, 
respectively) using anti-ATR antibody. WB was employed for analysis of co-
immunoprecipitation (Co-IP) of PARP1 with ATR. ATR was probed in WB using anti-
ATR antibody for loading control. The heavy chain of IgG serves as loading control. (D) 
Human HCT116 cells were treated with ionomycin followed by fractionation and ATR-
IP as mentioned in C. (E) A549 cells were treated with ionomycin (10 μM, 2 hrs) 
followed by PLA immunoassay to detect ionomycin-induced ATR-PARP1 binding using 
anti-ATR and anti-PARP1 antibodies and PLA technology. Fluorescent red dots indicate 
ionomycin-induced ATR-PARP1 complexes (20 X objective). The quantification the 
PLA assay is shown on the right side.  
 
The Anti-Necrosis Function of ATR Is ATR Kinase Activity Dependent 
Since it was demonstrated that ionomycin treatment induces ATR physical 
interaction with PARP1 (Figure 13C-13E) and ATR is well known as a protein kinase, it 
is of interest to determine whether ATR phosphorylates PARP1. Thus, A549 cells were 
treated with ionomycin (10 μM) (Figure 14A). WB analysis of the cell lysates show that 
ionomycin-induced phosphorylation of ATR at threonine 1989 was time-dependent. It 
was demonstrated that Thr-1989 phosphorylation is a marker for activation of ATR 
kinase (Nam 2011). We hypothesized that the kinase activity of ATR is essential for its 
anti-necrosis role. U2OS cells were dominant negative mutant. After 16-24 hours 
doxycycline (5 μg/mL) induction, ATR-wild type (WT) protein expressed in U2OS ATR-
WT cells and ATR-kinase dead (KD) protein expressed in U2OS ATR-KD cells. Figure 
14B shows that ionomycin-induced ATR-PARP1 binding occurred in U2OS ATR-WT 
cells but not in U2OS ATR-KD cells. As shown in Figure 14C, PI staining assay shows 
that U2OS ATR-KD cells had significantly more ionomycin-induced necrosis than U2OS 
ATR-WT cells. The quantification of the assay is shown as Figure 14D. The kinase 
activity of ATR-WT protein and ATR-KD protein in U2OS cells was confirmed in 
Figures 27A and 27B. Mammalian expression ATR-WT and ATR-KD plasmids were 
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transiently expressed in ATRflox/- cells separately. Figure 14E shows that cells (ATRflox/- 
cells) transiently expressed ATR-WT protein were much more resistant to ionomycin-
induced necrosis than cells (ATRflox/- cells) transiently expressed ATR-KD protein. These 
results (Figures 14B-14E) indicate that ATR kinase activity is required for ionomycin-
induced ATR-PARP1 binding and enables cells to be more resistant to ionomycin-
induced necrosis. In addition, shCTRL and shPARP1 cells were treated with ionomycin 
in the presence of VE822. The trypan blue exclusion assay shows that inhibition of ATR 
did not affect the percentage of necrosis induced by ionomycin treatment in PARP1 
deficient (shPARP1) cells. By contrast, in the presence of PARP1 (shCTRL cells), 
inhibition of ATR significantly increased the ionomycin-induced necrosis (Figure 14F). 
The result indicates that ATR and PARP1 work in the same ionomycin-induced necrosis 
pathway.  
 
 
Figure 14 (continued to the next page) 
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Figure 14. The anti-necrosis function of ATR is ATR kinase activity dependent. (A) 
A549 cells were treated with ionomycin (10 μM) as indicated, followed by WB analysis 
of the phosphorylation of ATR at threonine 1989 using anti-pATR-T1989 antibody. The 
positive control of phosphorylation of ATR at threonine 1989 was from A549 cells 
treated with 40 J/m2 UV followed by 2 hours recovery. (B) U2OS ATR-WT and ATR-
KD cells were treated with doxycycline (5 μg/mL) for 16-24 hours for induction of ATR-
WT and ATR-KD protein expression, followed by ionomycin or mock treatment for 4 
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hours. ATR IPed from whole cell extract (WCE) using anti-ATR antibody, followed by 
WB analysis of PARP1 that was co-IPed with ATR using anti-PARP1 antibody. Heavy 
chain of IgG was used as a loading control. The experiment was done by Dr. Benjamin A. 
Hilton. (C & D) ATR-WT and ATR-KD protein in U2OS ATR-WT and U2OS ATR-KD 
cells induced as mentioned in B, followed by ionomycin or mock treatment for 2 hours. 
The percentage of necrotic cell death was measured by PI staining assay via fluorescent 
microscopy (20 X objective) (C). The quantification of the data from C is shown in D. (E) 
ATR-WT and ATR-KD plasmids were transiently transfected into ATRflox/- cells for two 
days, followed by ionomycin treatment (10 μM, 4 hours). The percentage of necrotic cell 
death was measured using trypan blue exclusion assay. WB analysis of ATR-WT and 
ATR-KD protein expression in ATRflox/- cells using anti-ATR antibody. (F) shCTRL and 
shPARP1 cells were treated with ionomycin (10 μM, 4hrs) in the presence or absence of 
ATR inhibitor VE822 (10 μM, 1hr pre-incubation), followed by trypan blue exclusion 
assay to measure the percentage of necrotic cell death.  
 
 
Ca2+ Hyper-Activates the PARylation Activity of PARP1 and Primes PARP1 for ATR 
Binding 
Figure 26 and Figure 12 demonstrate that ionomycin treatment-induced 
intracellular Ca2+ concentration spike and hyper-activated PARylation activity of PARP1. 
A hypothesis was that Ca2+ by itself can hyper-activate PARP1. An in vitro PARylation 
assay with isotope NAD+-32P (Fischer et al. 2014) was performed to test the hypothesis. 
If adding Ca2+ could hyper-activate PARP1 by forming PAR polymers, it shows that 
hyper-activation of PARP1 is Ca2+ dependent. The full-length of PARP1 protein on the 
SDS-PAGE gel is around 110 kD, the smeared bands above 110 kD are PAR-modified 
PARP1. Figure 15A (lanes 4 and 5), shows that adding activated DNA oligos into 
PARylation reaction buffer (PRB) can activate PARylation activity of PARP1 as 
expected. There were PAR polymers (lane 5) shown as smear bands compared with little 
or no PAR polymers (lane 4). Interestingly, Ca2+ by itself can activate PARP1 to generate 
PAR polymers, the smeared bands between 110 kD and 150 kD, on PARP1 without 
activated DNA oligos (mimic DNA damage) (lane 3). While those smeared bands were 
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around 110 kD when purified ATR was incubated in PARylation reaction buffer with 
Ca2+ and PARP1 at the same time (lane 2 & lane 3). The bands around 110 kD represents 
that the PAR polymers on PARP1 were much shorter than the PAR polymers on PARP1 
represented by bands concentrated around 150 kD. Next experiment, Ca2+ was added to 
the whole cell lysate buffer followed by ATR-IP to allow the analysis of the PARP1 co-
IPed from ATR via WB analysis. As shown in Figure 15B and 15C, adding Ca2+ into the 
lysate buffer did induce ATR-PARP1 binding (Figure 15B) and more PARP1 co-IPed 
with ATR as higher concentrated Ca2+ added into lysate buffer (Figure 15C). Figure 15A 
indicates that Ca2+ hyper-activates PARP1. Figure 15B and 15C suggest that Ca2+ 
overload may primer PARP1 for ATR binding. All these results lead to the hypothesis 
that ATR binding to the PAR-modified PARP1 is the cause of ionomycin-induced ATR-
PARP1 binding. Poly(ADP-ribose) glycohydrolase (PARG) is an enzyme which is 
responsible for PAR hydrolysis to release ADRr from proteins at the PAR modification 
sites of protein, leaving MAR-modified proteins (Vyas et al. 2014). It was used in our 
experiment to check whether ATR tends to bind PAR-modified PARP1 or not. Purified 
PARP1 protein was IPed followed by in vitro PARylation assay. The PAR modified 
PARP1 was treated with or without PARG, followed by incubating with purified ATR 
protein. As shown in Figure 15D, WB analysis shows that ATR bound to PARP1 only 
treated with PARylation assay. Instead, ATR did not bind to PARP1 treated with 
PARylation assay firstly then followed by PARG incubation. The result indicates that 
ATR tends to bind PAR-modified PARP1 instead of MAR-modified PARP1. 
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Figure 15. Ca2+ itself hyper-activates the PARylation activity of PARP1 and may prime 
PARP1 for ATR binding. (A) In vitro, the PARylation activity of PARP1, with different 
proteins or chemicals, was performed by PARylation assay using NAD+, [32P]. Protein 
PARP1 incorporated with NAD+, [32P] was separated on 8% SDS-PAGE gel, followed 
by gel transferring to PVDF membrane. The PARylated PARP1 was shown by radio 
autography imaging. (B) A549 cells were ionomycin (10 μM, 4 hrs) or mock treated, 
followed by lysing in buffer AB with or without 1 μM Ca2+ as indicated. ATR was IPed 
from each lysate using anti-ATR antibody, then WB analysis was employed to analysis 
PARP1 co-IPed with ATR via PARP1 antibody. Both ATR and heavy chain of IgG 
probed as loading controls. (C) A549 cells were ionomycin (10 μM, 4 hrs) treated, 
followed by lysing in buffer AB with or without Ca2+ as indicated. ATR IPed from lysate, 
and WB analysis was employed to detect PARP1 co-IPed with ATR as mentioned in B.  
(D) Purified PARP1 was IPed using anti-PARP1 antibody, followed by in vitro 
PARylation assay. PAR-modified PARP1 was treated with or without PARG, followed 
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by incubating with purified ATR protein.  WB analysis was employed to analysis ATR 
that co-IPed with PARP1 via using ATR and PARP1 antibody. 
 
 
Mass Spectrometric Determination of the Potential ATR Phosphorylation Site on PARP1 
and PARP1 Plasmid Mutagenesis 
Figures 13 and 14 show that ATR kinase activity is required for ionomycin-induced ATR 
physical interaction with PARP1, and ATR kinase activity is needed for suppressing 
ionomycin-induced hyper-activation of the PARylation activity of PARP1. The 
hypothesis was that ATR may phosphorylate PARP1. Mass spectrometry was used to 
detect the candidate ATR phosphorylation site(s) on PARP1. PARP1 was IPed from 
ionomycin- or ethanol (mock)-treated A549 cells as mentioned in Figure 16A, followed 
by SDS-PAGE gel electrophoresis and coomassie blue staining. Band A and band B were 
cut out from SDS-PAGE gel separately for mass spectrometry to detect phosphorylation 
site(s) on PARP1. Mass spectrometry analysis (Figure 16B) shows that 66.32% of 
threonine (Thr) 368 on PARP1 was phosphorylated in mock-treated cells, while 99.98% 
was phosphorylated in ionomycin-treated cells. WB analysis confirms that cells had more 
PARP1 phosphorylated at Thr 368 in ionomycin-treated cells than in mock-treated cells 
using anti pPARP1-T368 antibody, shown in Figure 16C. It is of interest to examine the 
ionomycin-induced necrotic cell death and ATR-PARP1 interaction in cells that have 
mutated PARP1 protein at site T368 versus cells that have wild type PARP1. PARP1 
plasmid mutagenesis was done to generate the mutated PARP1 protein at site 368 from 
Thr to Ala. Figure 16D shows the sequence alignment of the mutated mammalian 
expression human PARP1-T368A plasmid with PAPR1-WT plasmid. It confirmed that 
cDNA sequence of PARP1 was mutated from ACG (Thr) to GCG (alanine, Ala). 
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Figure 16. Mass spectrometry to determine the candidate ATR phosphorylation site on 
PARP1. (A) Coomassie blue staining of PARP1 IPed from mock or ionomycin-treated 
A549 cells on 8% SDS-PAGE gel. (B) Phosphorylation site on PARP1 detected by mass 
spectrometry. (C) WB analysis of phosphor-PARP1 at threonine 368 in A549 cells 
treated with ionomycin (10 μM, 4 hrs) or mock. (D) PARP1-T368A plasmid sequence 
alignment with PARP1-WT plasmid. 
 
 
Other Potential ATR Phosphorylation Sites on PARP1 
 
In addition to mass spectrometry, SQ/TQ motifs of PARP1 are considered to be 
candidate ATR phosphorylation sites (Traven and Heierhorst 2005; Kim et al. 1999; 
O’Neill et al. 2000). There are six sites on PARP1 which are SQ/TQ motifs as shown in 
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Table 13. It is of interest to check the ionomycin-induced necrotic cell death and ATR-
PARP1 interaction in cells expressing mutated PARP1 protein at each of those candidate 
ATR phosphorylation sites respectively, compared with cells that have wild type PARP1. 
Site-directed mutagenesis of those six sites on PARP1 was done to generate mutated 
PARP1 protein with each site mutated to alanine. Figures 17A-17F show the sequence 
alignment of PARP1-WT plasmid with each mutated PARP1 plasmid (PARP1-S179A, 
PARP1-T325A, PARP1-S721A, PARP1-S727A, PARP1-S874A and PARP1-S911A).  
Table 13. SQ/TQ motifs on PARP1 
SQ/TQ SQ TQ 
Amino acid number 179,721,727,874,911 325 
 
 
 
Figure 17 (continued to the next page) 
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Figure 17. Site-directed mutagenesis of PARP1-WT plasmid. (A) – (F) Sequence 
alignment of PARP1-WT with each mutated PARP1 plasmid (PARP1-S179A, PARP1-
T325A, PARP1-S721A, PARP1-S727A, PARP1-S874A and PARP1-S911A). 
 
 
Candidate Ca2+ Binding Site (CaBS) on PARP1 
Ca2+-binding proteins usually containing EF hand domain. EF hand loop of EF 
hand loop is important for Ca2+ binding and it is composed of 12 amino acids (Lewit-
Bentley 2000). Based on the consensus of EF hand loop (Figure 18A), the fragment of 
PARP1 from aspartic acid (Asp, D) 957 to D968 was shown as a potential Ca2+-binding 
site with 92% similarity with consensus of EF hand loop (Figure 18A). The PARP1 
fragment (D957-D968) is named here as Ca2+-binding site (CaBS). Since aspartic acids in 
the EF hand are important for Ca2+ binding (Bentley 2012), D965 or/and D968 sites were 
chosen to be mutated to asparagine (N). As shown in Figure 18B, the sequence alignment 
of PARP1-WT plasmid with mutated PARP1-D968N plasmid shows that cDNA 
sequence of PARP1 was mutated from GAC (D) to AAC (N). Figure 18C shows the 
sequence alignment of PARP1-WT plasmid with mutated PARP1-D965D968N plasmid 
in which the cDNA sequence of PARP1 was mutated from GAT (D965) to AAT (N965) 
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and from GAC (D968) to AAC (N968). Figure 18D shows the sequence alignment of 
PARP1-WT plasmid with PARP1-∆CaBS plasmid where the cDNA fragment of CaBS is 
deleted from PARP1-WT plasmid. A549-shPARP1 cells will be used as transiently 
expressing PARP-WT and PARP1-∆CaBS plasmids separately. In vitro PARylation 
assay will be employed to test whether both PARP1 proteins’ activity hyper-activation is 
Ca2+ dependent or not. 
 
Figure 18. Determine the candidate Ca2+ binding site (CaBS) on PARP1. (A) The 
fragment of PARP1, D957-D968, was shown as a candidate calcium binding site (CaBS) 
based on protein database scanning via PATTINPROT online from “PRABI-GERLAND 
PHONE-ALPES BIOINFORMATIC POLE GERLAND SITE”. Consensus pattern for 
calcium-binding of EF hand loop is “D-x-[DNS]-{ILVFYW}-[DENSTG]-[DNQGHRK]-
{GP}-[LIVMC]-[DENQSTAGC]-x(2)-[DE]” (modified from website 
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“http://www.uniprot.org/help/ca_bind”). The interpretation of standard International 
Union of Pure and Applied Chemistry (IUPAC) one-letter codes, ‘x’ any amino acid is 
accepted at the position, ‘[]’ residues indicated in square parentheses are those allowed at 
the position, ‘{}’ residues indicated in curly brackets are those forbidden at the position. 
‘-’ separates each pattern element. (B) PARP1-WT was mutated to PARP1-D968N. (C) 
PARP1-WT mutated to PARP1-D965ND968N. (D) PARP1-WT was mutated to PARP1-
∆CaBS with CaBS deletion. 
 
 
PARP1-WT Plasmid Site-Directed Mutagenesis at Glutamic Acid (Glu, E) 988 
Glutamic acid (E) 988 on C-terminal catalytic domain of PARP1 was previously 
shown to be essential for the synthesis (especial the elongation) of enzyme-linked PAR 
polymers (Rolli et al. 1997). Mutation of E988 on PARP1 to lysine (Lys, K) or glutamine 
(Gln, Q) was reported to lead to the MAR modification only (Chapman et al. 2013). 
Figure 19A shows the sequence alignment of PARP1-WT plasmid with mutated PARP1-
E988K plasmid as the cDNA sequence of PARP1 mutated from GAG (E) to AAG (K). 
Figure 19B shows the sequence alignment of PARP1-WT plasmid with mutated PARP1-
E988Q plasmid as the cDNA sequence of PARP1 mutated from GAG (E) to CAG (Q). 
A549-shPARP1 cells will be used as transiently expressing PARP-WT, PARP1-E988K 
and PARP1-E988Q plasmids separately. After ionomycin treatment, PARP1 will be co-
IPed together with ATR. WB will be employed to analyze whether ATR tends to bind 
either PAR-modified or MAR-modified PARP1. 
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Figure 19. PARP1-WT plasmid site-directed mutagenesis at glutamic acid (Glu, E) 988 
residue. (A) Plasmid PARP1-WT was mutated to PARP-E988K. (B) Plasmid PARP-WT 
was mutated to PARP1-E988Q. 
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CHAPTER 4 
DISCUSSION 
 
ATR Plays an Anti-necrosis Role in Response to Ionomycin-Induced NDDR 
ATR is well known for its regulatory role in DDR as a checkpoint kinase. For 
example, in response to UV irradiation-induced DNA damage, ATR plays a role in 
suppressing apoptosis through the ATR-Chk1 pathway (Heffernan et al. 2009) or directly 
at mitochondria via interacting with tBid (Hilton et al. 2015). In addition, ATR promotes 
nucleotide excision repair (NER) via physical interaction with xeroderma pigmentosum 
group A (XPA) (Wu et al. 2007; Shell et al. 2009). Our work indicates that ATR plays a 
role in response to NDDR for the first time. As shown in Figure 10G, DNA damage and 
DDR markers, γH2AX, pp53-S15, pChk1-S345 (Liu et al. 2000; Meek 2009; Mah et al. 
2010), were not detected in the ionomycin-treated cells using WB analysis, while all of 
them were detected in UV-irradiated cells.  
Trypan blue exclusion assay (Figures 10A, 10C, 10D and 10E) and CellTiter blue 
cell viability assay (Figure 10B) were performed to measure ionomycin-induced the rate 
of cell death in percentage in ATR-deficient, ATR-proficient and ATR-knockdown cells 
respectively. All results suggest that ATR may play a role in suppressing the ionomycin-
induced cell death. Cell morphology-based assay (Figure 11A and 11B) and HMGB1 
release assay (Figure 10F) also support the anti-necrosis function of ATR. Furthermore, 
WB analysis of the cleavage of caspase-3, caspase-7 and PARP1 (Figure 11D and 11D) 
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and trypan blue exclusion assay using apoptosis inhibitor Z-VAD-FMK (Figure 11E) 
demonstrate that ATR possesses an anti-necrosis function in cells.  
The concept of ATR plays an anti-necrotic role in respond to NDDR in cells is 
pretty novel and has not been proposed or studied previously. Necrosis was believed a 
disorderly and unregulated process and ATR is well known for its regulatory role in DDR 
as a checkpoint kinase. Our data show that ATR possesses an anti-necrosis function in 
cells and figuring out the mechanism behind it turns out to be very interesting. 
 
Ionomycin-Induced Hyper-Activation of PARylation Activity of PARP1 Is Ca2+ 
Dependent  
Ionomycin is well known as a Ca2+ ionophore to raise intracellular level of Ca2+. 
It induces intracellular Ca2+ concentration and induces necrosis (Hermann 1978; Vaseva 
et al. 2012). The intracellular Ca2+ concentration during ionomycin treatment was 
measured using Fura-2. In our experiment, ionomycin treatment raises the intracellular 
Ca2+ concentration. As shown in Figure 26, the intracellular Ca2+ concentration increased 
immediately once cells were treated with ionomycin, and the concentration reached ~700 
nM in ATR-proficient cells and ~1 µM in ATR-deficient cells 10 minutes after 
ionomycin incubation. Under physiological conditions, cells maintain a cytosolic free- 
Ca2+ concentration of roughly 100 nM. A spike of cytosolic Ca2+ to 200-400 nM due to 
release from the endoplasmic reticulum (ER) can induce apoptosis. In contrast, a 
cytosolic overload of Ca2+ resulting from influx across the plasma membrane triggers 
necrosis (McConkey and Orrenius 1996; Zong and Thompson 2006). The result from 
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Figure 26 indicates that ionomycin incubation (10 μM, 4 hrs) may initiate necrosis by 
inducing the intracellular Ca2+ concentration overload.  
Active PARP1 hydrolyzes NAD+ into NAM and ADPr and covalently transfers 
ADPr to its substrates or itself to form 90% of PAR polymers within cells (D’Amours et 
al. 1999; Amé et al. 2004; Bürkle 2005; Yelamos et al. 2011; Vyas et al. 2014). 
Excessive consumption of NAD+ is the cause of necrosis due to the cellular metabolism 
collapse. Lactate dehydrogenase (LDH) release assay (Figure 12I) showed that supplying 
media with NAD+ can rescue cells from ionomycin-induced necrosis. Why? One 
explanation may the NAD+ pool depletion is caused by ionomycin-induced hyper-
activation of PARP1. As shown in Figure 12B, 12C and 12D, cells either treated with 
potent PARP1 inhibitors or transfected with siPARP1 are devoid of ability of to form 
PAR polymers after ionomycin treatment.  Figures 12E, 12F and 12G further confirm 
that PARP1 is required for ionomycin-induced formation of PAR polymers and necrosis.  
The next question is how ionomycin treatment induces hyper-activation of 
PARP1? Several papers reported that Ca2+ as a mediator of necrotic cell death is 
responsible for the hyper-activation of PARP1-induced necrosis due to NAD+/ATP 
depletion in cells (Bentle et al. 2006; Yang et al. 2007; Francis et al. 2013; Douglas and 
Baines 2014; Zhang et al. 2014). But no mechanism study was mentioned. The present in 
vitro work (Figure 15A) showed that Ca2+ can hyper-activate PARP1. As the positive 
control, adding activated oligo DNA in the PARylation reaction buffer (PRB) can hyper-
activate PARP1, which is shown as the formation of PAR polymers (Figure 15A, lane 4 
and lane 5). Interestingly, PAR polymers were formed in PRB with Ca2+ instead of 
activated oligo DNA (Figure 15, lane 3). Ca2+ itself can hyper-activate PARP1. Maybe 
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there is CaBS on PARP1 as we have identified a potential CaBS on PARP1 which has a 
consensus sequence pattern with EF hand loop (Figure 18A). PARP1 plasmids with site-
directed mutation at CaBS were produced for future determination of the mechanism of 
Ca2+-dependent hyper-activation of PARP1. The future study of Ca2+-dependent hyper-
activation of PARP1 via CaBS may help us to define how Ca2+ hyper-activates PARP1. 
 
Ionomycin Treatment Induces ATR-PARP1 Binding and ATR Modifies the Full-Length 
PAR Polymer Formation   
Our work demonstrates that ionomycin treatment induces ATR-PARP1 binding in 
cells (Figure 13C-E), and the binding appears to suppress necrosis via inhibiting 
formation of full-length PAR polymers formed by PARP1 (Figure 13A and 13B, Figure 
15A). ATR’s kinase activity is involved in suppressing ionomycin-induced necrosis 
(Figure 14B-E), but what it is mentioned here focus on ATR-PARP1 binding through 
PAR modification. Ionomycin-induced formation of PAR polymers largely increased in 
cells treated with ATR inhibitor or lacking ATR protein (Figure 13A and 13B). In vitro 
co-IP experiment (Figure 15D) showed that ATR binds to PARylated PARP1, as much 
less ATR binds to PARG-treated PARylated PARP1.The result of the in vitro 
PARylation assay (Figure 15A) suggests the mechanism that ATR-PARP1 binding itself 
may play a role in suppressing the formation of PAR polymers. As shown in Figure 15A 
lane 2, lane 3 and lane 4, adding purified ATR protein (without ATRIP and ATP) already 
inhibited the PARylation activity of PARP1, which shows the suppression of formation 
of full-length PAR polymers. Furthermore, ATR-PARP1 binding is induced in co-IP 
buffer containing Ca2+ as shown in Figure 15B and 15C. The results indicate that PARP1 
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hyper-activation is Ca2+ dependent. But why Ca2+ overload induces ATR-PARP1 binding? 
PAR is highly negative charges due to the two phosphate groups of each ADP-ribose 
subunits (Figure 5) (Leung 2014). Those negative charges PAR polymers intrinsically 
tend to bind to positive charged protein surface. May ATR have the positive charged 
surface to bind to the shortly PAR-modified PARP1 to inhibit the further extension of 
PARP1 spatially due to ATR is a big protein. As a result, a hypothesis was proposed that 
ATR tends to bind the short PAR-modified PARP1to spatially inhibit the PARylation 
activity of PARP1. 
In 1995, glutamic acid (E) 988 on the C-terminal catalytic domain of PARP1 was 
found to be essential for the synthesis (specific the elongation) of enzyme-linked PAR 
polymers. E988Q, E988A and E988K mutant PARP1 proteins were almost devoid of 
elongation activity (2800-fold reduction) (Rolli et al. 1997; Chapman et al. 2013). 
Mammalian expression plasmids PARP1-E988Q and PARP1-E988K were built and will 
be used for future determination of the mechanism of ATR binding to PAR modified 
PARP1.  
  
The Anti-Necrosis Function of ATR Is ATR Kinase Activity Dependent and ATRIP 
Independent 
The present work shows that the kinase activity of ATR is needed for its anti-
necrosis function. Ionomycin-activated kinase activity of ATR (Figure 14A) and 
ionomycin-induced ATR-PARP1 binding is ATR kinase activity dependent (Figure 14B). 
Cells containing ATR-KD protein are much more sensitive to ionomycin-induced 
necrosis than cells containing ATR-WT protein (Figure 14C-E).  
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It was reported that ATRIP in the nucleus forms a complex with ATR and is 
essential for the DNA damage checkpoint activity of ATR (Cortez 2001; Burrows and 
Elledge 2008). Figure 15A (lane 2, 3, 6 and 7) shows that purified ATR can suppress 
Ca2+-activated PARylation activity of PARP1, while purified ATR cannot suppress 
activate oligo (mimic DNA damage)-activated PARylation activity of PARP1. It 
indicates that the mechanism of ATR in response to DDR and NDDR is not same. Since 
ionomycin induces NDDR in cells, whether ATRIP is dispensable for the novel role of 
ATR needed to be studied via more research study. 
Since ionomycin treatment activates the kinase activity of ATR and induces ATR 
physically interacting with PARP1, which indicates that ATR phosphorylates PARP1 
while they binding. Even though the data of Figure 15A shows that, without ATP and 
ATRIP, purified ATR could inhibit the extension of PARylation of PARP1. That might 
be the ATR-PARP1 binding itself is to inhibit the PARylation activity of PARP1 
spatially. The kinase activity of ATR does play a role in helping ionomycin-treated cells 
from necrosis. Figure 16 shows that threonine 368 on PARP1 is a candidate 
phosphorylation site via mass spectrometry. Mammalian expression human PARP1-
T368A plasmid was built for future mechanism research. Based on the SQ/TQ motif of 
ATR (Traven and Heierhorst 2005), 6 candidate phosphorylation sites were found on 
PARP1 as shown in Table 4. The PARP1-S179A, -T325A, -S721A, -S727A, -S874A and 
–S911A plasmids were built for future mechanism research as shown in Figure 17. 
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Summary 
The present work reveals that ATR plays a role in suppressing the ionomycin-
induced necrotic cell death is part of NDDR. As summarized in Figure 20, ionomycin-
induced necrosis is caused by Ca2+ overload-induced hyper-activation of PARP1, which 
leads to excessive consumption of NAD+ pool in cells followed by cellular metabolism 
(ATP pool) failure. During this process, little or no DNA damage stress is induced as no 
DDR markers can be detected. ATR plays a role in suppressing necrosis through physical 
interaction with PARP1 and suppresses the excessive consumption of NAD pool. In vitro, 
the PARylation activity of PARP1 was inhibited to allow the long full extensive PAR 
polymers on itself when ATR together with PARP1 are incubated in the PARylation 
reaction buffer. ATR prefers to bind PAR-modified PARP1 instead of MAR-modified 
PARP1. The results mentioned above indicate ATR plays an anti-necrosis role in 
ionomycin-induced necrotic cell death.  
Figure 20: ATR plays a role in NDDR wherein it is able to suppress ionomycin-induced 
PARP1-mediated necrosis.  
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APPENDICES 
 
ATR Protein Purification 
It is demonstrated in our lab that DNA damage (particularly UV damage) induced 
an electrophoretic mobility shift of cytoplasmic but not nuclear ATR. The induced-
cytoplasmic ATR migrated slower in 3%-8% gradient SDS-PAGE than the nuclear or 
non-induced cytoATR and is designated as ATR-H relative to the latter (ATR-L). Two 
lots of recombinant ATR were purified from HEK293T cells transfected with a 
pcDNA3.1-ATR WT overexpression construct. As shown in Figure 21A, the purified 
ATR co-migrated with the ATR-H form using WB analysis. Using Pierce 660 nm protein 
assay as shown in Figure 20C, the purified ATR-H was 124 μg/mL. And the purified 
ATR-H can be visualized by coomassie blue staining (Figure 21B) (Figures 21A and 21B 
are copied from Hilton et al. 2015).  
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Figure 21. ATR protein purification. (A) WB analysis of two lots (1 and 2) of 
recombinant ATR protein using anti-ATR antibody. Recombinant ATR protein was 
purified from HEK293T cells using anti-FLAG antibody. Purified ATR has the same 
electrophoretic mobility as endogenous ATR-H from UV-treated HCT116 cells. (B) 
Recombinant ATR purified from HEK293T cells, followed by coomassie blue staining of 
purified ATR on SDS-PAGE gel. (C) Standard curve for measurement of purified ATR 
using Pierce 660 nm protein assay. 
 
 
siRNA Knockdown of Peptidylprolyl Isomerases in A549 Cells 
Since the observation of ATR-H in the UV-treated cytoplasmic fraction, it is of 
interest to know how it is formed after irradiation. It was shown that, upon DNA damage, 
phosphorylation did not cause the ATR shift (Liu et al. 2011, Nam et al. 2011). The same 
was true for modifications by glycosylation, ubiquitinylation, sumoylation, 
palmitoylation, prenylation, and N-myristoylation. Also, ATR-H is not a biosynthetic 
precursor to ATR-L as it occurred with translation inhibitors. Alternatively, this mobility 
shift may reflect a backbone conformational change that persists in SDS-denaturing gel 
electrophoresis. Since isomerization of peptidyl-propyl bonds may confer a backbone 
conformational change (Zhou and Lu 2016), possible isomerization of ATR was 
examined. Prolyl isomerases cyclophilin-40 (CyP40), cyclophilin-A (CyPA), and Pin1 
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are known to be active in the cytoplasm. As shown in Figure 22, Pin1 depletion resulted 
in formation of ATR-H even in the absence of UV (comparing ratios of ATR-H to ATR-
L in lane 1 versus lane 7), depletion of CyP40 and CyPA had little effect (lane 1 versus 
lanes 3 or 5) (copied from Hilton et al. 2015).  
Figure 22. siRNA knockdown of indicated peptidylprolyl isomerases in A549 cells. It 
shows that ATR-H formation increases in the cytoplasm of non-irradiated A549 cells 
only after Pin1 knockdown (lane7) (copied from (Hilton et al. 2015). 
 
 
Pin1 Protein Purification 
GST-tagged Pin1 construct was transformed into E.coli (BL21 (DE3)) and 
expression induced with IPIG (1 mM) as indicated in Figure 23A. Induction of GST-Pin1 
expression at 30°C was chosen based on the result of coomassie blue staining of cell 
lysate on SDS-PAGE gel (Figure 23A). GST-Pin1 was induced to express at 30°C for 
indicated period (Figure 23B). 5 hours incubation period was chosen for GST-Pin1 
expression based on the result of coomassie blue staining of cells lysate on SDS-PAGE 
gel as shown in Figure 23B. Figure 23C shows the coomassie blue staining of purified 
GST-Pin1 protein in 10% SDS-PAGE gel. Purified GST-Pin1 protein is 500 μg/mL in 10% 
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glycerol and 1000 μg/mL in 50% glycerol after overnight dialysis based on the standard 
curve built via using Pierce 660 nm protein assay, as shown in Figure 23D.  
Figure 23. GST-Pin1 protein purification from E.coli (BL21 (DE3)). (A) GST-Pin1 
protein was induced to express in E.coli (BL21 (DE3)) at indicated incubation 
temperature, followed by coomassie blue staining of cell lysate on SDS-PAGE gel. (B) 
GST-Pin1 were induced to express in E.coli (BL21 (DE3)) at 30°C with indicated 
incubation period, followed by coomassie blue staining of cell lysate on SDS-PAGE gel. 
(C) Coomassie blue staining of purified GST-Pin1 on SDS-PAGE gel. (D) Standard 
curve for measurement of purified GST-Pin1 using Pierce 660 nm protein assay. 
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Sequence Alignment of BH3 Domains in Bcl2 Family Proteins with ATR Protein 
Protein sequence alignment of ATR with several Bcl2 family members reveals 
that ATR contains three potential BH3-like domains, a hallmark of Bcl2 family proteins 
(copy from Hilton et al. 2015).  
Figure 24. Sequence alignment of BH3 domains in Bcl2 family proteins with ATR 
protein. In the consensus BH3 sequence, ɸ represents a hydrophobic residue, Z a 
hydrophilic residue, D/E an acidic residue, A/G a small residue, K/R a basic residue, and 
X any residue. Three candidate BH3 domains were observed: ATR (175-187), ATR (462-
474), and ATR (2345-2357) (copy from Hilton et al. 2015).  
 
ATR cDNA Fragment (A359-N484, ATRf) Subclone 
It is demonstrated that the backbone change of ATR by peptidylprolyl isomerase 
Pin1 is the reason for the mobility shift of cytoplasmic ATR after UV treatment. S428 
P429 site on ATR is the substrate site of Pin1 for the backbone change. It is of interest to 
subclone the ATR fragment (A359-N484, ATRf) and ATRf containing site mutation of 
P429A, containing BH3-like domain and Pin1 isomerization site, in plasmid vector for 
protein expression and structure analysis. Compared with ATR protein which is 
composed of 2644 aa, the ATRf and ATRf containing site mutation of P429A are much 
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small with 126 aa, which may be more easy and convenient for structure and mobility 
shift analysis. ATR fragment (A359-N484, ATRf) was chose for subcloning into vector 
pTYB2. pTYB2 is an E. coli cloning and expression vector (7474 bp) used to insert the 
target protein into its multiple cloning sites (MCS). This results in the fusion of the C-
terminal of the target protein to the N-terminal of the intein tag.  IMPACTTM Kit allows 
the thiol-induced self-cleavage of the intein releases the target protein form the chitin-
bound intein tag, resulting in a single column purification of the target protein. As shown 
in Figure 25A, NheI and XhoI in the MCS of vector pTYB2 were chosen for subcloning 
the ATR fragment (A359-N484). As shown in Figure 25B, agarose gel electrophoresis 
showed undigested and single restriction enzyme-digested or double restriction enzyme-
digested vector pTYB2. ATRf PCR fragment is also shown in Figure 25B. The results 
indicate that both vector pTYB2 and ATRf PCR fragments are corresponding to the 
expected sizes. After the subcloning, pTYB2-ATRf was restriction enzyme double 
digested by NdeI and XhoI, followed by agarose gel electrophoresis of pTYB2 with same 
double digestion and the ATRf PCR fragment. Figure 25C shows that pTYB2-ATRf 
construct was built, as the digested big fragment from pTYB2-ATRf is the same size as 
the digested pTYB2 (lane 4, 5, 6 vs lane 2) and the digested small fragment from pTYB2-
ATRf is the same size as the ATRf PCR fragment. The pTYB2-ATRf construct sent out 
for sequencing to check whether the ATRf PCR fragment containing the correct ATR 
fragment sequence or not. As shown in Figure 25D, the ATRf subcloned into vector 
pTYB2 is 100% match to the ATR (A359-N484) fragment cDNA sequence. The green 
color bar indicated the identity. As shown in Figure 25E and 25F, the C-terminal of the 
His-tag connects to the N-terminal of the ATRf fragment, and NdeI and XhoI restriction 
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sites on vector pTYB2 are on pTYB2-ATRf construct. The results confirm that ATRf 
fragment is inserted in pTYB2 vector and with His-tag at the N-terminal of ATRf 
fragment. The same method was employed for subcloning the ATR fragment (A359-
N484) containing mutagenesis at site P429A into vector pTYB2. Figure 25G shows the 
subclone works as ATR fragment (A359-N484, P429A) is 100 matches the ATR (A359-
N484) fragment expect P429A mutation. 
 
 
 
 
Figure 25 (continued to the next page) 
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Figure 25 (continued to the next page) 
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Figure 25. ATR cDNA fragment (A359-N484, ATRf) subclone. (A) The multiple cloning 
sites (MCS) of pTYB2 vector (modified from the datasheet of pTYB2 vector, 
https://www.neb.com/products/n6702-ptyb2-vector). (B) Agarose gel electrophoresis of 
vector pTYB2, with or without restriction enzyme digestion as indicated, and ATR 
cDNA PCR fragment (A359-N484, ATRf). (C) Agarose gel electrophoresis of pTYB2, 
pTYB2-ATRf with or without restriction enzyme double digestion. (D) Sequence 
alignment of cDNA of ATRf with construct pTYB2-ATR (A359-N484). (E) The His-tag 
and NdeI enzyme cDNA sequence on construct pTYB2-ATR (A359-N484). (F) The 
XhoI enzyme cDNA sequence on construct pTYB2-ATR (A359-N484). (G) Sequence 
alignment of cDNA of ATRf with construct pTYB-ATRf P429A. 
 
Cellular Ca2+ concentration measurement after ionomycin treatment in ATR+/+ and 
ATRflox/- cells 
Ionomycin, a Ca2+ ionophore, was used in research to induce necrosis by 
increasing intracellular Ca2+ concentration (Hermann 1978; Vaseva et al. 2012). As 
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shown in Figure 26, the intracellular Ca2+ concentration began to increase immediately 
upon ionomycin added into cell culture media. The Ca2+ concentration reached to 700 nM 
in ATR-proficient cells and almost reached to 1000 nM in ATR-deficient cells after 10 
minutes of ionomycin incubation. Intracellular Ca2+ concentration began to drop 
immediately after the cells were placed in Ca2+-free media with ionomycin. The result 
shows that the ionomycin treatment does generate an intracellular Ca2+ overload.  
Figure 26. Cellular Ca2+ concentration measurement after ionomycin treatment in ATR+/+ 
and ATRflox/- cells. ATR+/+ and ATRflox/- cells were incubated with intracellular calcium 
indicator Fura-2 before ionomycin treatment. Intracellular Ca2+ concentration was 
measured for 10 minutes once ionomycin was added to Ca2+ containing cell culture 
media, followed by another 10 minutes of measurement of ionomycin treatment in non- 
Ca2+-contained media. The experiment was done by Dr. Robert Wondergem. 
 
Testing of ATR-WT and ATR-KD Protein Function in Cells 
The WB analysis results of Figure 27A and 27B shows that doxycycline 
incubation induces expression of ATR-WT and ATR-KD protein in ATR-WT and ATR-
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KD cells. ATR-KD is ATR protein loss its kinase activity since there is none or little 
phosphorylation of Chk1 at serine 345 detected after UV treatment. 
Figure 27. Test of kinase activity of ATR-WT and ATR-KD proteins in U2OS ATR-WT 
and ATR-KD cells. (A) U2OS ATR-WT cells were incubated with doxycycline for 16-24 
hours to induce ATR-WT expression. WB analysis of ATR protein expression using anti-
ATR antibody. (B) ATR-WT and ATR-KD cells were induced to express ATR-WT and 
ATR-KD proteins respectively as mentioned in A, followed by UV-C treatment with 2 
hours recovery. WB analysis of DDR role of ATR using anti pChk1-S345 antibody. 
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